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Background: Current tools for TB diagnosis have suboptimal accuracy, perform 
poorly in diagnosing extra-pulmonary TB, and are not point of care; hence results have 
a slow turn-around time.  
Objective: This project evaluated the diagnostic accuracy of the promising novel loop 
mediated isothermal amplification (LAMP) assay on sputum, and that of the semi-
automated Xpert MTB/RIF (Xpert) test on non-sputum specimens (bronchoalveolar 
lavage fluid [BALF], tracheal aspirates, and cerebrospinal fluid [CSF]) from South 
African patients with suspected TB (the accuracy of Xpert using these fluids was 
unknown at the time this work was performed).  
Methodology: Biological samples (sputum, tracheal aspirates, BALF, or CSF) were 
collected from patients with suspected TB. Liquid culture served as the reference 
standard for the diagnosis of definite TB. Accuracy was evaluated according to HIV 
and smear microscopy status, where appropriate. The relationship between test 
performance and bacterial load (culture time-to-positivity [TTP]) was also compared. 
For the evaluation of LAMP, 2 spot sputa of approximately 4 ml were collected from 
301 patients (60 µl of sputum was used for the assay). For the evaluation of Xpert on 
BALF, 152 patients who were sputum scarce or smear-negative were recruited (1 ml of 
the BALF aliquot or a re-suspended pellet from 10 ml BALF was used). For the 
evaluation of Xpert on tracheal aspirates, 120 tracheal aspirates from patients enrolled 
in the intensive care unit (ICU) were tested. For the evaluation of Xpert on CSF, 235 
patients with suspected TBM had a lumbar puncture with 1 ml of CSF or where 
available a re-suspended pellet from 3 ml of CSF evaluated using Xpert. 
Results: Using sputum samples the sensitivity of LAMP was similar to that of smear 
microscopy [(77%, 95% CI 67-84%) versus (67%, 95% CI 56-76%; p=0.134), 
respectively], whereas the specificity of LAMP was suboptimal compared to smear 
microscopy [(91%, 95% CI 86-94%) versus (99.5%, 97-99%; p<0.003), respectively]. 
In HIV-infected patients compared to HIV-uninfected patients the sensitivity of LAMP 
was 70% (54-82%) versus 85% (69-93%); p=0.545, and the specificity was 91% (82-
96%) versus 89% (82-93%); p=0.702, respectively, but PPV was similar [(81%, 65-
91%) vs. (70%, 55-82%); p=0.291, respectively]. There was a shorter TTP in LAMP-
positive patients vs. LAMP-negative patients [16 [IQR: (4-50)] vs. 40 days (6-50); 
x 
 
p<0.0001]. By contrast using BALF, Xpert significantly outperformed smear 
microscopy [93% (77-98%) versus 58% (39%-74%); p<0.004, respectively]. HIV co-
infection was associated with a significantly increased TTP in BALF (23.58 vs. 21.48 
days; p=0.02), whilst there was no correlation between Xpert MTB/RIF generated cycle 
threshold values (CT) and TTP (p=0.09; R2=0.654). Centrifugation of the BALF had no 
incremental diagnostic value having sensitivity of 95% (75-99%) when Xpert was used. 
Using tracheal aspirates Xpert had a significantly higher sensitivity compared to smear 
microscopy [91% (62-98%) versus 55% (28-79%); p=0.08]. Using CSF the sensitivity 
of Xpert was higher than smear microscopy [49% (33-64%) versus 3% (1-15%); 
p<0.001, respectively]. In HIV-co-infected patients, centrifugation of CSF resulted in a 
significant increase in the sensitivity of Xpert compared to uncentrifuged CSF [100% 
(68-100%) vs. 53% (37-69 %); p=0.01, respectively]. 
Conclusions:  In those patients with suspected pulmonary TB, and using sputum, the 
LAMP assay had incremental yield over smear microscopy, while specificity was 
suboptimal (< 95%). By contrast when using non-sputum samples Xpert significantly 
outperformed smear microscopy using BALF in sputum-scarce or smear-negative 
cases, and using tracheal aspirates in the ICU. In the setting of EPTB, Xpert had good 
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SIGNIFICANCE AND OBJECTIVES OF THE STUDY 
Study Significance 
TB associated deaths account for almost 2 million people yearly. Factors such as a 
collapse in health standards, coupled with HIVco-infection and a surge in DR-TB have 
compounded the impact of the disease [1]. Rapid, sensitive, point-of –care molecular 
TB diagnostic techniques are of significance in eradicating or thus reducing the burden 
of TB in both resource-poor and resource-advantaged countries. Such techniques 
should provide a platform that is easy to use and generate results within a short time 
frame, and should be highly sensitive and provide more specificity than the 
conventional methods (smear microscopy and culture) currently being used. 
Furthermore, such techniques should be able to diagnose EPTB and drug susceptibility 
in patients. So far, the Xpert MTB/RIF test has obtained endorsement from the WHO 
as a rapid TB molecular platform especially in countries devastated by the disease.  In 
summary, the WHO has outlined the use of Xpert particularly in individuals coming 
from those areas with greatest risk of the disease having HIV co-infection and/or in 
individuals from areas with increased risk of MDR-TB. Another promising novel 
diagnostic tool is the LAMP test, which is a simple and sensitive test for the molecular 
detection of TB in developing country settings. However, its diagnostic accuracy at the 
primary level of patient care has not been established yet, such that further research is 
needed to compare its performance against the conventional modes of diagnosis 
currently at hand. The results thereof, if positive, will guide in the roll-out of the test 
especially at point-of-care within primary care settings in developing countries that are 
at greatest risk of the TB scourge.   
Objectives 
1. To determine the diagnostic accuracy of the manual LAMP platform on a single 
spot sputum collected from TB suspects at primary health care centres in Cape 
Town, South Africa vs. concentrated florescence smear microscopy and liquid 
culture for the diagnosis of pulmonary TB.  
2. To validate the sensitivity and specificity of Xpert in BALF for the diagnosis of 
sputum scarce and or smear-negative TB. 
xix 
 
3. To evaluate the performance outcomes of Xpert using tracheal aspirates in ICU 
patients for diagnosing pulmonary TB. 







1.1. TUBERCULOSIS CAUSE, CLINICAL PRESENTATION AND 
EPIDEMIOLOGY 
 
Tuberculosis (TB) is a respiratory disease falling amongst the top 10 causes of 
mortality globally [2]. TB  mostly affects the lungs and this form of TB is known as 
pulmonary tuberculosis [3], while EPTB occurs at sites other than the lung, such as 
meningitis (affecting the central nervous system), Pott’s disease of the spine (affecting 
bones and joints), the lymphatic system (scrofula of the neck), kidneys (urogenital 
TB) and the skin [4].  
 
1.2. TUBERCULOSIS GLOBAL BURDEN AND PREVALENCE 
TB is a global  major health threat [2]  that has become a global public health 
epidemic [5]. Of the total world’s population, at least one third of the individuals are 
reported to be infected with M. tuberculosis [6] with approximately 2 million deaths 
occurring on a yearly basis due to TB infection [7-9]. Globally, new TB infection is 
estimated to be greater than 9 million cases, making it significantly higher than all 
recorded periods before [5, 7, 10]. The World Health Organization (WHO) reported 
that in 2008, sub Saharan Africa’s estimated incidence rate was believed to be twice 
that of South-East Asia with over 350 cases per 100 000 population [8].  
TB prevalence is greatest in resource poor countries such that approximately 80% of 
all active TB cases worldwide have been reported to be occurring within such  
communities [7]. Amongst the new TB cases (approximately 9 million) reported, 15% 
occurred in HIV-infected individuals where Africa was having 31% from this total 




recorded approximately 1037 cases per 100,000 individuals [12]. TB prevalence has 
however escalated as a result of the emergence of HIVco-infection amongst other 
possibilities [12, 13]. 
 
1.3. SPREAD OF TUBERCULOSIS 
TB is an infectious, respiratory disease caused by Mycobacterium tuberculosis 
complex (MTBC) strains. The mode of transmission is via inhalation of  droplet 
nuclei [8, 14]. Mycobacterium tuberculosis (M. tuberculosis)-positive patients are 
highly responsible in the transmission of TB within  communities [10] with close 
contacts suffering the most in terms of getting the disease [15].  
 
 
1.4. SIGNS AND SYMPTOMS OF TUBERCULOSIS 
A persistent cough lasting at least 3 weeks, bloody sputum and chest pain are amongst 
the most observed signs and symptoms of PTB while weight loss, fever, night 
sweating,  intermittent episodes of fatigue, loss of appetite are also observed signs and 
symptoms in cases of TB infection in patients [13, 16]. 
 
1.5. MULTI DRUG-RESISTANT AND EXTENSIVELY DRUG-
RESISTANT TUBERCULOSIS 
The widespread misuse of isoniazid together with rifampicin which are first line drugs 
in the treatment of TB  coupled with the emergence of drug resistant TB has resulted 
in the occurrence of multi drug resistant (MDR) and extremely drug resistant (XDR) 
TB [9, 17]. MDR-TB is as a result of M. tuberculosis  that has inherent resistant 
properties to isoniazid and rifampicin while XDR TB is as a result of M. tuberculosis 
resistant to first-line drugs such as rifampicin and isoniazid, any floroquinolone and 
either capreomycin, kanamycin and amikacin [18].  
Prevalence of drug resistant tuberculosis and global surveillance of DR-TB 
About 440 000 MDR-TB incidences occurred globally, with approximately 150 000 




numbers of reported cases globally contributing at least 50% of the global burden, 
followed by Russia which had slightly around 9% and sub Saharan Africa with at 
least 14% of the new global recorded MDR-TB cases, Figure 1 [17]. 
Figure 1: The global coverage and surveillance for MDR-TB prevalence [Adapted 
from Migliori et al.[17]]. 
 
1.6. TUBERCULOSIS, HIV CO-INFECTION AND ASSOCIATED 
DIAGNOSTIC DIFFICULTIES 
The escalating TB epidemic is directly related to HIV infection within the general 
populace [19], especially within Sub-Saharan Africa where the highest TB and HIV 
rates have been recorded globally [4, 17].  
With increased immunosuppression amongst HIV-positive individuals, EPTB and 
mycobacteremia seems to be highly likely (see Figure 2). This is because T 
lymphocytes, macrophages and dendritic cells afford the host immune prowess 
towards TB infection as a result of the various cascade of cytokines that are produced. 
Th-1 lymphocytes produce interferon-gamma which is central to antimycobacterial 
immune defence through limiting M. tuberculosis growth [12]. 
In a post-mortem study which was conducted in KwaZulu Natal, Scott et al. [20] 




amongst HIV-positive patients as a result of the diagnostic delay and possible late 
treatment regimens in TB patients. HIV infection positively impacts on TB as there is 
a rather close relationship with an onset of EPTB  as a result of the impaired host’s 
inflammatory response due to much lower frequency of cavitation in the lungs, 
leading to frequent smear-negative TB and an accompanying long time to culture- 
positivity of liquid cultures [6]. This occurs as the individual at first has proper 
immunological control and few  bacterial numbers (quiescent infection), followed by 
the progressive disruption of immunological function (active infection) as a result of 
rising bacillary numbers and the eventual appearance of TB-associated symptoms (see 
Figure 2) such that  active infection is increased by HIV co-infection [5]. 
With this in mind, employing techniques such as the LAM test, culturing blood and 
aspirating lymph nodes can be of utmost importance in cases of sputum scarce 
patients. 
 
Figure 2: Graph showing the rising total bacillary load of M. tuberculosis over time 





1.7. STRUCTURAL MORPHOLOGY OF MYCOBACTERIUM 
TUBERCULOSIS 
M. tuberculosis is cocco-bacillary in terms of structural morphology with sizes 
averaging at least 0.6 µm in width and 4 µm in length [21]. The bacterium is an acid 
fast, obligate aerobe that has limited motility. Organisms form colony-like clumps 
when in broth culture [22], Figure 3. 
 
Figure 3: Mycobacterial growth in broth culture [Adapted from Pena et al. [22]]. 
 
1.7.1. Mycobacterium tuberculosis cell wall constituents 
M. tuberculosis is an intracellular parasite that resides within the macrophage. M. 
tuberculosis can neither be classified as Gram-positive or negative species. M. 
tuberculosis has an inner plasma membrane made up of phospholipids, coupled with 
an outer peptidoglycan layer. Further plasmic membranes do exist, and this gives the 






1.7.2. Cell wall composition 
The inner plasmic membrane is composed of arabinogalactan, whereas the outer layer 
has mycolic acid. Approximately, more than 65% of lipids make up the cell wall of 
the bacterium with mycolic acids, Cord factor and wax-D as the major lipid 
constituents. Hydrophobic properties are conferred by the mycolic acids on the 
extracellular layer which thus prevent disinfectants from entering the cell. The 
mycolyl-AG-peptidoglycan complex (MAPc) forms the core component of this 
envelope [23]. The markedly observed specific s-shaped cords (chains of cells) 
especially when M. tuberculosis colonies are grown in vitro, is as a result of the Cord 
factor component which is mainly found in virulent strains of mycobacterial species. 
The extracellular envelope is made up of Wax D which aids in immunogenicity [23].  
 
The biochemical complex formations that are formed between cell surface receptors 
termed the Mannose Receptor (MR) proteins found on the macrophage and the 
pathogen are brought about by the interactions of the surface glycolipids [24]. LAM 
binds to the MR present on the cell surface of the macrophage, thereby causing 
conformational changes to the structure of the cell wall, inactivating it in the process, 
creating an immune free system that results in mycobacteremia, while LAM also 
scavenges for reactive oxygen species that aid in M. tuberculosis growth [25, 26]. It is 
this LAM that molecular assays have been developed for diagnosing TB infection 












1.8. TB DIAGNOSTICS 
1.8.1. Conventional modes of TB diagnosis 
1.8.1.1. Microscopy 
Sputum smear microscopy and culturing of M. tuberculosis especially in marginalized 
resource-limited countries remain the core TB diagnostic techniques available [27]. 
Microscopy exists as the primary mode of TB diagnosis in such marginalized set ups  
[28] and provides an index of contagiousness [27, 29]. Smear microscopy is a 
relatively simple technique, while it is also inexpensive especially for the general 
populace who might need the test to be carried out. Amongst its drawbacks is that, in 
cases of HIV co-infection , disseminated disease and paediatric TB  the test is not 
sufficiently effective, resulting in increased mortality rates due to misdiagnosis [28, 
30]. Also the need for experienced professionals that might not be readily available 




Culture is the golden standard for diagnosing the presence of MTBC strains while it 
offers drug susceptibility testing as well [29, 31, 32].  Two types of culture exist, 
which are solid culture (Lowenstein Jensen) and liquid culture (MGIT liquid culture 
960). The major disadvantage culture has is that it is time consuming for both the 
diagnostic process and drug susceptibility testing, with  Lowenstein Jensen (LJ) 
cultures taking between 20 to 56 days and between 28 to 42 days respectively [31]. 
HIV-infected   individuals and minors find it difficult to expectorate sputum, such that 
culture will eventually miss EP forms of TB, where EPTB is highly likely in immuno-
compromised patients and causes high mortality rates in such populations [31].  
 
1.8.1.3. Radiography 
The absence of specific radiological markers associated with TB leads to this 




highly likely as a result of Chest X-rays which might show normal compatibility, 
where a patient might actually have active PTB resulting in many false negatives.  
Thus the traditional modes of diagnosing TB take long to produce a result and require 
technical expertise that might not be readily available necessitating the need for novel 
molecular methods to address these drawbacks. 
 
1.8.2. Antigen-based diagnostic methods 
An alternative way of diagnosing TB is through antigen detection. A minimum 
concentration threshold of at least 20 mg/mL is useful for mycobacterial antigen 
detection on different body fluids. Amongst the antigens used in the detection of TB 
are antigenA60, LAM, cord factor, antigen 5, PPD, P32 antigen amongst others [34]. 
Commercial tests detecting the presence of antigens have been developed for specific 
bio-samples [31]. However, antigen based methods have the disadvantage of being 
unable to distinguish between latent and active infection. 
 
1.8.2.1. LAM urine test (Alere, USA) 
The assay detects LAM in urine of TB infected patients [31]. LAM forms part of the 
bacterial cell envelope and confers heat resistant properties to the bacterium, where in 
TB infected individuals, LAM is ultra-filtered by the kidney and found in their urine  
[35]. Urine is sterile and thus safe to deal with, while its collection is simple as 
compared to obtaining sputum or other bio-samples.  
Several studies have been carried out on commercial LAM tests using ELISA on 
urine in detecting TB. In one study, when solid or liquid culture was used as a 
reference standard, the sensitivity of the test was 51%, while having a specificity of at 
least 90% [35]. They also reported an increase in sensitivity of about 62% particularly 
in patients infected with HIV [35]. Similarly, in a study by Peter et al. [36], the 
sensitivity of LAM was 60% in sputum-scarce patients who were HIV-infected. 
The use of the LAM test as a solo diagnostic test will not be useful to sufficiently 
rule-in / rule-out TB due to the modest sensitivities realised. Coupled with smear 




especially within HIV-infected populations who are highly immuno-compromised 
[35].   
1.8.2.2. Protein assays (Proteome Systems, Australia) (still under review) 
The test being developed has the capability to test on most bio-samples such as blood 
products (plasma and whole blood), saliva and sputum. Guillerm et al. [31], reported 
that  though preliminarily, the test can be able to detect those mycobacterial species 
specific antigens allowing for active TB diagnosis.  
 
1.8.3. Nucleic acid amplification techniques (NAATs) 
Nucleic acid amplification (NAA) testing in clinical medicine is of vital importance, 
as it allows genetic screening and disease diagnosis [37]. NAATs targeting M. 
tuberculosis have enormous potential to improve TB case detection and thus provide a 
more timeous result than the existing conventional modes of TB diagnosis together 
with the biochemical platforms [38].  In culture-positive, smear positive (C+S+) 
patients, NAA testing provides a more sensitive platform in diagnosing TB, while 
providing with reduced sensitivity within culture-positive, smear-negative (C+S-) 
patients. 
1.8.3.1. Commercial nucleic acid amplification tests 
Several companies have standardized nucleic acid amplification tests commercially 
which have widely benefited in the diagnosis of PTB. However, documented studies 
have rather somewhat variable information on the performance characteristics of these 
tests and thus indeterminative in comparison to the standard methods for TB diagnosis 
[39]. It is however imperative that such commercial tests be used in conjunction with 
microscopy as documented by the US Centre for Disease Control (CDC).  
Polymerase chain reaction methods have been established to detect mycobacterial 
strains [40]. The Food and Drug Administration (FDA) has endorsed use of the 
Enhanced Mycobacterium tuberculosis direct test (E-MTD; Gen- Probe, San Diego, 
CA) and the Amplicor Mycobacterium tuberculosis test (Amplicor, Roche Diagnostic 
Systems, Inc., Branchburg, NJ) [38, 39, 41, 42], Table 1. The two tests are primarily 
for the detection of acid fast species in patients who haven’t been initiated on TB 





1.8.3.1.1. Amplicor Mycobacterium tuberculosis test  
MTBC organisms possess a specific ribosomal gene, the 16S rRNA which is 
amplified by specially designed primers [40, 41]. A segment of this gene is amplified, 
which has a specific code that allows complimentarity with specific oligonucleotides 
for mycobacterial species. Contamination is limited through the addition of dUTP and 
a restriction enzyme which can either induce false-positive results [41]. Following the 
decontamination process by sodium hydroxide, clinicians and patients can expect 
results in about 6 ½ hrs, Table 1. A computerised system, the Cobas Amplicor is thus 
available in developed countries. The test has been shown to be highly specific and 
sensitive in M. tuberculosis diagnosis particularly amongst S+C+ sputum samples with 
rather reduced sensitivity in S-C+ sputum samples [40]. Clinical evaluation studies of 
the test have given sensitivity of between 80% - 92%, and specificity of at least 99% 
[41]. European countries are already using this test, while it is still waiting for 
endorsement in the USA. 
 
1.8.3.1.2. Enhanced Mycobacterium tuberculosis Direct Test  
The test is fundamentally based on amplification of a transcript, whereby the basic 
principle that starts the process is as a result of a pre-sonication step that disrupts the 
cell and results in  rRNA being  released from the bacterial  [41]. A complex is 
formed between the bacterial rRNA and a promoter-primer which initiates 
amplification. rRNA is reverse transcribed  to form a cDNA-RNA hybrid resulting in 
the primary ribonucleic acid template in being degraded giving rise to promoter 
number 2 binding to the complimentary-DNA extending it in the process, giving rise 
to ds-cDNA that has a DNA-dependent RNA polymerase further initiating 
transcription such that new ribosomal ribonucleic acid molecules are formed [41].  
The clinical sensitivity and specificity of this test has been found to be between 91% - 
95% and 99% - 100%, respectively, especially when using respiratory samples for 
both acid fast S+C+ and S-C+ samples [41]. However, interms of performance 
outcomes compared to culture, there seem to be no significant difference, but most 




management, as E-MTD takes one day (3 ½ hrs), while culture takes between 14-28 




Table 1.Comparison of commercially available (Amplicor, E-MTD) and Xpert 
MTB/RIF nucleic acid amplification tests for the detection of M. tuberculosis 
complex organisms. 
Characteristic Amplicor E-MTD Xpert MTB/RIF 
Manufacturer Roche Gen-Probe Cepheid 
Amplification 
platform 
PCR TMA Nested, real-time 
PCR 
Target 16S rRNA rRNA rpoB gene 
Ability to detect 
drug resistance 
No No Yes (RIF) 
Analytical 
sensitivity 
≥ 20 orgs N/A 131 CFU/ml 
Clinical sensitivity 79- 92% 91– 95% 98.2 % 
Clinical specificity 99 - 99.9% 98 – 100% 99.2% 
Sensitivity for AFB 
smear-positive 
specimens 
41- 73% 80 – 100% 73% 
PPV 92.6 - 96.6% 83.3 – 100% 85% 


































Definition of abbreviations: E-MTD; Enhanced Mycobacterium tuberculosis Direct 
Test, TMA; Transcription-mediated amplification, rRNA; ribosomal ribonucleic acid, 
PCR; polymerase chain reaction, CFU; colony forming units, RIF; rifampicin, AFB; 
acid fast bacilli, FDA; Food and drug administration, MDR; multi drug resistant. 
 
1.8.3.2. NAATs in use today 
There is a diagnostic delay and possible misdiagnosis in cases of EPTB,  smear-
negative TB and disseminated disease especially when HIV co-infection is involved , 
as smear microscopy solely will not be able to pick-up cases of TB in such situations 
[43]. 
1.8.3.2.1. What is the Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA) assay? 
This is a NAA platform that is automated, self regulatory, with limited hands on time, 
incorporating sample processing, nucleic acid extraction, amplification, TB detection 
and RIF-resistance [44]. This test avails results directly from raw samples through 
combining a short preparative process of the sample coupled with the automated PCR 
stage within two hours [45]. 
 
1.8.3.2.2. How Xpert MTB/RIF works? 
The test can thus be carried out using unprocessed sputum samples or processed 
sputum pellets [46]. The only non-automated step for this assay involves the addition 
of a sample buffer to sputum, followed by transferring two mls of this sputum-buffer 
solution into the cartridge, where it then gets inserted into the Xpert chamber, availing 
results in approximately two hours, Figure 4. The test specifically targets MTBC 
organisms, while it allows for drug susceptibility testing (RIF-resistance) through 
amplifying the rpoB gene particularly the rifampin resistance determining region [46] 
which gets probed by molecular beacons for mutations within this RRDR [44]. 




The lytic buffer is mixed in the ratio of 2 parts to 1 part of the sample (2:1 
respectively), followed by shaking the mixture, which is then incubated at room 
temperature for at least 5 minutes followed by shaking once more. 2 ml of the sample 
reagent mixture is then transferred to the Xpert test cartridge and then placed on the 
Xpert chamber module.  Proceeding steps thereafter become automated and the result 
is printable, with “MTB detected, RIF resistance not detected” [44].   
 
 








1.8.3.2.4. Xpert MTB/RIF assay diagnostic accuracy and its impact     
Xpert has a limit of detection (LOD) of at least 131 colony forming units (CFU) per 
ml of sputum, which thus is an index of the number of viable bacteria detected with 
95% confidence [47].  
As shown in Table 2, in a prospective, multicentre study, Boehme and colleagues 
noted that of the 561 patients tested amongst C+ patients, 551 (98%) patients had S+ 
TB, whereas, of the 171 patients with S- disease, the test picked up 124 (73%) 
patients, while having a specificity of 99% (604 of 609 patients) [44]. In this study, 
out of 205 patients tested for drug resistance, 202 were picked up by the test (98%), 
while of the 514 patients with Rifampicin sensitive bacteria, the test correctly picked 
up 504 subjects (98%), where they concluded that was sensitive in the detection of 
TB, while also picking up RIF-resistance from unprocessed sputum, availing results 
within 2 hrs. 
Helb et al. [47], in their study in Vietnam noted that out of 107 patients consecutively 
enrolled and suspected of TB, the test identified all 29 (100%) cases to be having 
C+S+ TB, while in S- individuals, the test had a sensitivity of 72% (38 of 53, 95%CI 
57-83%). 
In another study, Theron et al., noted that overall, Xpert MTB/RIF sensitivity was 
95%, while having specificity of 94% amongst S+ individuals, whereas in S- 
individuals, the sensitivity was 55%, where the analysis was restricted to a ml of raw 
sputum [48]. 
Table 2. Summary of studies outlining the diagnostic accuracy of Xpert MTB/RIF in 
diagnosing TB. 
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1.8.3.2.5. Limitations of the Xpert MTB/RIF assay 
Amongst some of the Xpert assay drawbacks is that it is expensive to run a test (see 
Table 4), with the cost ranging from between USD22,63 to USD27,55 and 
USD17,000 per 4 module instrument, whereas a single sputum smear examination 
costs between USD1,13 to USD1,63 with LJ and MGIT cultures costing between 
USD13,56 to USD18,95 [59]. Another drawback is that the assay only tests for 
rifampicin resistance which is a platform that has too few occuring mutations. 
However, as a result of all these drawbacks especially the high costs involved and 
cold chain storage of buffers and cartridges, there is need for affordable, easy to 
operate and fast producing result systems bringing point of care to patients. Promising 
new diagnostic techniques, such as isothermal amplification platforms act as potential 
candidates in the diagnosis of TB. 
 
1.8.3.3. Loop mediated isothermal amplification (LAMP) 
Pathogen detection from clinical bio-specimens is paramount in directing appropriate 
therapy and treatment regimens in affected patients. Existing traditional techniques 
such as culture and microscopy tend to be time consuming amongst various factors 
thereby prolonging the time to diagnosis and treatment for the suffering patient.  
The LAMP reaction is a novel test amplifying nucleic acids under isothermal 
conditions [37]. Unlike the polymerase chain reaction, the template strand need not be 
denatured [60]. It is a relatively simple technique, where a water bath is only needed 
to provide with the constant temperature, thereby making it a low cost technique 
which is favourable for use in high burdened, resource poor countries. 
The loop mediated isothermal amplification assay relies on a DNA dependent 
polymerase that initiates amplification and elongates the template strand where four 
specially designed primers specifically recognize six distinct sequences on the target 
DNA [61, 62]. To further accelerate the reaction, two extra loop primers can be added 
to the reaction cocktail [63]. The LAMP technique has successfully been applied in 




1.8.3.3.1. LAMP primer design 
The test makes use of a pair of inner and another pair of outer primers, with the early 
stages of the reaction requiring all the two sets of the primers for efficient 
amplification. For the later stages of the reaction, only the inner primer pair is needed 
necessitating strand displacement synthesis. The outer primer pair is comprised of F3 
and B3, while the inner primers are thus FIP and BIP. These inner primers do possess 
specific codes corresponding to the sense and antisense strands of the target 
mycobacterial nucleic acid where they are involved in priming activities [37]. The 
LAMP assay is thus a faster process due to additional loop primers [forward loop 
primer (LF) and backward loop primer (LB)]. A DNA polymerase enzyme catalyzes 
the reaction at a temperature range between 60-65 °C, which is also conducive for 
primer melting. 
 
1.8.3.3.2. Molecular mechanism of the loop mediated isothermal amplification 
reaction 
The LAMP start up cocktail possess a catalytic enzyme (Bst DNA polymerase), 
specific primers, dNTPs, and the target DNA template all carried out at a fixed 
isothermal temperature range for approximately an hour. Three sequential steps exist 
which are thus the synthesis of bio-molecules necessary to start up the reaction, cyclic 
amplification which is proceeded by the elongation of strands, and lastly the recycling 
phase of accumulating end products [37]. For the start up phase, a complex is formed 
between the forward inner primer (FIP) and F2c which is complimentary and found 
on the DNA of choice forming an FIP-F2c complex. Strand displacement DNA 
synthesis is initiated by a complex formed which is thus termed the F3-F3c complex, 
which results in the release of end products (loop structures with complementary 
sequences at one end). A stem loop structure of DNA is formed as a result of single 
stranded DNA (ssDNA) hybridizing with BIP and further priming by B3 signifying 
the cyclic phase of the reaction.  The cyclic phase of the LAMP test involves the 
hybridization of the forward inner primer to the loop component of the stem creating a 
complex which through disruption of bonds leads to the formation of tandem arrays of 




phases of the test, involve a further stem loop with complementary sequences to the 
original strand, and the gapped tandem repeat DNA that has been repaired by the 
enzyme which eventually serve as start up material for proceeding cyclic phases. The 
end product is a DNA molecule with several inverted stem loops of different sizes 














Figure 5: Molecular mechanism of the LAMP reaction [Adapted from Notomi et al. 
[37]]. 
 
1.8.3.3.3. Visualization of loop mediated isothermal amplification 
Positive LAMP reactions can be visualized using a variety of methods. Gels can be 
used which are thus stained by dyes such as ethidium bromide and electrophoresis 
carried out to visualize products. The LAMP products visualized under UV light can 
be seen as stem and loop structures resembling a ladder-like appearance on the gel. 
The addition of a dye, SYBR Green 1 stain which has affinity to bind to DNA enables 
direct visualization [64]. In order to reduce contamination and allow for direct 




before the initial amplification phase and viewed under UV light [60]. Real-time 
monitoring of turbidity through the use of a turbidimeter is also a way of monitoring 
positive test results, thus through the accumulation of salts (magnesium 
pyrophosphate) within the reaction mixture.  
 
1.8.3.4. Loop mediated isothermal amplification platforms targeting different 
MTBC genes 
1.8.3.4.1. LAMP targeting the gyrB gene 
a. Iwamoto and colleagues in their study specifically targeted the gyrB gene to 
detect mycobacterial species in the sputum of suspected TB patients [62]. In 
this study, they had a cohort of 24 MTBC species and 7 non-mycobacterial 
species, where they held their reaction mixture at a fixed temperature of 63 °C 
[62].  
 
b. Boehme et al.[65], carried out a multicentre trial in Peru, Tanzania, and 
Bangladesh using processed sputum and the reaction mixture was maintained 
at 67°C for 40 min. In this study, they changed parameters such as temperature 
and number of primers while focusing at the gyrB gene. Their study findings 
were that, LAMP had a sensitivity of 97% (173 of 177, 95% CI 96-99%) 
amongst S+C+ samples, while in S-C+ samples, the sensitivity was 48% (21 of 
43, 95% CI 34-64%).  
1.8.3.4.2. LAMP targeting the rrs gene 
In a study in Nepal, Pandey et al.[66], designed six species specific primers targeting 
the 16S rRNA gene found in MTBC organisms, where they analyzed 200 sputa 
samples with an isothermal temperature maintained at 64 °C for an hour. MTBC 
species exhibited efficient DNA amplification with this system where in C samples, 
the sensitivity was of the test was 100% (96/96) [66].  
1.8.3.4.3. LAMP targeting the Insertion Sequence 6110 (IS6110) gene 
In a study by Aryan et al. [33], the repetitive IS6110 sequence was used as a target 




that their assay was almost 20 times highly sensitive than the basic conventional PCR 
for the same gene. Also in comparing their findings where they targeted the IS6110 to 
the previously mentioned genes (gyrB and rrs), sensitivity was 50: 20 times higher 
respectively.  
 
1.8.3.5. Advantages of LAMP  
LAMP has the ability to amplify DNA at low constant isothermal temperatures 
allowing low cost equipment to be used for its operation [33, 65, 67]. The test’s 
cocktail incorporates primers, the DNA dependent polymerase Bst, and the sample 
which are maintained at specific temperatures usually between 60-65°C and upon 
amplification, results visualized and this is done in a single step process [37]. 
Conventional PCR involves the initial denaturation of the template whereas the 
LAMP test is void of that stage. There is no need for a thermal cycler for LAMP to 
proceed making it a user friendly and simple diagnostic technique in clinical medicine 
especially in less developed countries with limited resources [68]. The constant 
isothermal temperatures coupled with the use of a single catalytic and proof reading 
polymerase makes the loop mediated isothermal amplification assay a quicker 
technique [33, 37, 62, 66]. LAMP-positive results are easily visualized as a white 
precipitate due to the accumulation of magnesium pyrophosphate ions within the 
reaction mixture making it turbid [69]. Unlike conventional PCR, the LAMP test is 
tolerant to inhibition greatly especially from items like culture medium and salts that 
build-up during the process which can have a direct bearing effect on the 
amplification efficiency especially during PCR [68]. Comparing the LAMP assay 
interms of end products, to conventional PCR, it has approximately 50 times more 
efficiency [33]. 
Techniques that alleviate and result in more rapid diagnoses, benefit not only the 
patient interms of early treatment but can also ease pressure on the possibly dwindling 
resources by governments and should be rolled-out within high burdened, resource 
limited countries. It is however for these factors that the LAMP test with attributes 
that may enable its application in less privileged set-ups has been developed and thus 




Table 3.Commercially available nucleic acid amplification tests (NAATs) for 
tuberculosis diagnosis in summary. 
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PCR amplification of 16s rRNA. 
Product detection is performed via 
colorimetric detection 
Roche Molecular Systems 
Branchburg, New Jersey 
Cobas® Amplicor PCR amplification of 16s rRNA Roche Molecular Systems 
Mannheim, Germany 
BD-ProbeTec Direct 
And the BD-ProbeTec 
ET 
Strand Displacement Amplification 
(SDA) technology for the direct, 
qualitative detection of 16s rRNA 
and the M. tuberculosis insertion 
sequence IS6110 
Becton-Dickinson 
Diagnostic Systems Sparks, 
Maryland 
Xpert® MTB/RIF Semi-quantitative nested real-time 
PCR in-vitro diagnostic test for the 
detection of M. tuberculosis complex 
DNA, and rifampicin-resistance 








Isothermal amplification and visual 
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1.8.3.6. Other amplification platforms 
1.8.3.6.1. Nucleic acid sequence based amplification (NASBA; bioMérieux, 
Boxtel, The Netherlands) 
Nucleic acid sequence-based amplification is a commercially available isothermal, in 
vitro amplification procedure that uses RNA as the specific amplification target [70, 
71]. The assay employs the simultaneous activities of reverse transcriptase, RNase 
and RNA polymerase enzymes which result in a single stranded-RNA product which 
is antisense to the original RNA template [37, 72]. NASBA has been successfully 
applied as a rapid system in the detection of astroviruses and in the monitoring of 
cytomegalovirus infections in transplant recipients as well.  
It makes use of the simultaneous enzymatic activities of avian myeloblastosis virus 
reverse transcriptase (AMV-RT), RNase H, and T7 RNA polymerase, under 
isothermal conditions (Figure 6). The constant temperature maintained throughout the 
amplification reaction allows each step of the reaction to proceed as soon as an 
amplification intermediate becomes available. Products of NASBA are single 
stranded and, thus, can be applied to detection formats using probe hybridization 
[70].The end products of NASBA can be detected using gel electrophoresis, 
fluorescence probes (real-time NASBA), and colorimetric assay [73, 74]. The FDA 
has approved the technique in NucliSence formulation (NASBAECL) for molecular 
detection of some microorganisms such as HCV and HIV-1 [74]. NASBA is highly 
compromised in its effective use as a diagnostic technique in that it requires relatively 





Figure 6: Simplified diagram representing NASBA [Adapted from Notomi et al. 
[37]]. 
The straight arrow represents the initiation phase while the circular arrow represents 
the cyclic phase. The activities of reverse transcriptase, RNase H, T7 RNA 
polymerase, and the primer-binding activities are also indicated. 
 
 
1.8.3.6.2. Transcription mediated amplification  
Reverse transcriptase is used to copy rRNA into a transcription complex which is then 
transcribed by DNA-directed RNA Polymerase to produce more rRNA molecules 
[40]. These transcripts serve as templates for reverse transcription and further 
amplification. The specificity of the assay primarily depends on the specificity of the 
oligonucleotides used in the hybridization assay. A TMA-Based Kit for the detection 
of MTB in sputum specimens was developed thus the MTD-Test, Gen-Probe, San 






Figure 7: Simplified diagram of the TMA method [Adapted from Niemz et al. [75]]. 
The RNA target is converted to ds cDNA with a promoter region through reverse 
transcription, followed by RNase H degradation of the original strand. DNA 
polymerization is initiated by a second primer. RNA polymerase (pol) amplification 
creates products that feed back into the original reaction [75]. 
 
 
1.8.3.6.3. Strand displacement amplification (SDA) 
This is an isothermal, in vitro method of amplifying a DNA target up to 108 fold at 40 
°C [32]. Such a technique is based upon the ability of a restriction enzyme to nick a 
hemi modified recognition site allowing the polymerase to displace a downstream 
DNA strand during replication [32, 37]. SDA has been used to amplify only a single 
target species in each reaction mixture, Figure 8. 
Recent advances have allowed the extension of the capability of such a technique to 
allow simultaneous and efficient amplification of two target sequences coupled with 
an internal control molecule designed to act as a standard (Multiplex SDA technique) 
which has the advantages of allowing the use of a single pair of amplification primers 
on a pair of different targets, thus ensuring that amplification proceeds at comparable 
rates and minimizing background amplification reactions as a result of errant priming 
events. The multiplex SDA method allows the IS6110 sequence to be amplified 
providing amplification level specificity for the MTBC strains  while the other target 
being the 16S ribosomal gene common to all clinically relevant mycobacterial species  
allowing mycobacterial genus specificity at the level of amplification.  
SDA has the disadvantages of having increased backgrounds due to digestion of 
irrelevant DNA contained in the sample, while it  also requires the use of costly 
modified nucleotides as a substrate making it impossible to be implemented in the 





Figure 8: Simplified diagrammatic representation of single-target SDA [Adapted 
from [76] ]. 
The target DNA is heat denatured in the presence of all reagents except the restriction 
enzyme and polymerase, after which amplification proceeds at approximately 40 °C 






Table 4. Comparison of the sensitivity, drug susceptibility testing, cost and the time to diagnosis of different diagnostic tools for active 
TB in children and HIV-TB co-infected patients. 














POC LAM n/a 50 20 n/a No 3.5 25 mins No 
LAM ELISA n/a 50 20 n/a No 3.5 1-2 days No 
Xpert MTB/RIF 75 82 90 70 Yes 14 2 hrs Yes 
Florescence smear 
microscopy 
20 40 70 n/a No 3.5 4 hrs - 2 
days 
Yes 
Roche Amplicor 66 overall 85 66 No 15 4 hrs - 2 
days 
No 
MTBDRplus overall sensitivity is 98% in S+ pts 60 Yes 15 4 hrs - 2 
days 
Yes 
MODS 40 90 95 n/a Yes 2.5 7 - 14 days Yes 
MGIT 40 80 90 n/a Yes 16 10 - 14 
days 
Yes 
LAMP overall sensitivity is 84% 60 No 6 2 hrs No 
Definition of abbreviations. Only tests commercially available have been included which are found in South Africa. GeneXpert 
MTB/RIF assay for frontline TB diagnosis in TB clinics. Line Probe Assays (LPA); genotypic drug susceptibility testing using Genotype 
MTBDRplus (Hain lifesciences, Nuhren, Germany), DST; phenotypic drug susceptibility testing using automated liquid culture; 




Waltham, MA, USA), MODS; microscopic observed drugs susceptibility; TBMODS Kit® 
(Hardy Diagnostics, Santa Maria, CA, USA), Cobas Taqman MTB (Roche Molecular 





2. CHAPTER 2 
 
Diagnostic accuracy of the loop mediated isothermal amplification (LAMP) 




The accuracy of nucleic acid tests such as LAMP when performed on sputum of 
patients suspected of pulmonary TB is limited. This study evaluated the diagnostic 
accuracy of the promising novel isothermal LAMP assay on sputum collected from 
South African patients suspected of TB. 
Methods 
301 South African patients had their sputa collected. Two spot sputa, approximately 4 
ml were collected per patient, with 60 µl of sputum being used for the LAMP test. 
Liquid culture was performed on sputa collected at the same time as that used for the 
LAMP test, where liquid culture served as a reference standard for definite TB. We 
evaluated accuracy according to HIV and smear microscopy status, when these data 
were available. Also, the relationship between test performance and TTP was 
compared. 
Results 
Of the 297 patients included, 58 were culture confirmed cases for TB (31% were 
HIV-positive). The sensitivity of LAMP [77% (95% CI 67- 84%] was similar to that 
of smear microscopy [67% (56-76%); p=0.134] while the specificity of LAMP was 
different to that of smear microscopy [91% (86-94%) vs. 99.5% (97-99%); p<0.003, 
respectively]. The sensitivity of LAMP was similar in HIV-infected vs. –uninfected 
patients (70% vs. 85%; p=0.545, respectively).  Amongst the 29 smear–negative 




significant shorter time to culture-positivity; [16 days (4-50)] than LAMP-negative 
patients; [40 days (6-50), p<0.0001]. 
Conclusion 
The LAMP assay had modest sensitivity, while it also had incremental yield over 
smear microscopy. The test also had suboptimal accuracy for the detection of 
pulmonary TB as the false positive rate was too high. Further development maybe 
required on the stability and sensitivity of the LAMP test for its application in the 






















Traditionally the diagnosis of TB disease has been done through culturing bacteria on 
agar plates followed by determining the phenotypic and serological properties of the 
pathogen [79], [80]. Attempts have been made using biochemical tests, however such 
techniques have insufficient sensitivity to detect low levels of pathogen and are often 
dependent of first culturing the pathogen [81]. Molecular techniques such as the 
polymerase chain reaction (PCR) can be used to speed up diagnosis and increase 
sensitivity and specificity of pathogen detection.  
 
Despite the availability of numerous diagnostic methods, there is no single rapid, 
sensitive, inexpensive and non- laborious method for field diagnosis of diseases such 
as TB. PCR techniques have significantly increased our ability to detect TB infection, 
but its requirement of a high-precision thermal cycler has prevented it from being 
widely used in the field or by private clinics as a routine diagnostic tool. The recently 
endorsed Xpert MTB/RIF assay recommended by the WHO as a “first-line” 
diagnostic test in endemic countries and for management of multi-drug resistant TB 
cases serves and incorporates most of these POC attributes and is useful for use in the 
field in TB diagnosis [82, 83]. 
 
Alternatively, isothermal nucleic acid amplification methods, which require only a 
simple heating block and obviate the need for thermal cycling, have been developed 
to offer feasible platforms for rapid and sensitive detection of a target nucleic acid. 
These include nucleic acid-based amplification (NASBA), loop-mediated isothermal 
amplification (LAMP), recombinase polymerase amplification (RPA) and 
ramification amplification [37, 72, 84, 85]. 
 
Boyle et al. [84], evaluated the RPA assay performance which is a rapid, low 
temperature isothermal DNA amplification reaction against indirect smear 
microscopy and found that it had a sensitivity of 91% (95% CI 85 - 98%) and 





The loop-mediated isothermal amplification (LAMP) assay is a gene amplification 
procedure, in which the reaction proceeds at a constant temperature catalyzed by one 
type of enzyme. It is a rapid assay (approximately between 35 to 60 mins [62]) and 
possess simple features making it different from the existing genetic tests currently 
available [37]. The LAMP method is able to amplify between 5 to 50 copies of DNA 
in less than an hour with no special reagents required [86]. The procedure is 
characterized by the use of 4–6 different primers specifically designed to recognize 
between 6-8 distinct regions on the target gene relying  on autocyclic strand 
displacement DNA synthesis catalysed by the Bst DNA polymerase large fragment, 
which has high specificity and sensitivity under isothermal conditions [62] making it 
to be a highly specific assay since it allows MTBC detection [33]. The reaction 
process proceeds at a constant temperature (60–65 °C) [37], [63]. Furthermore, in a 
LAMP assay, all steps from amplification to detection are conducted within one 
reaction tube under isothermal conditions. Visual detection is enhanced as a result of 
high amounts of insoluble magnesium pyrophosphate produced and fluorescence 
allowing it to be adopted in resource poor countries [33]. 
 
The above advantages can be used to prevent contamination, which can occur in PCR 
during the transfer of samples containing amplicons from tubes to gels for 
electrophoretic confirmation and thus omit the need for complicated temperature 
control, as required for PCR [60]. Owing to these advantages, the LAMP assay does 
not require well-equipped laboratories to be performed, with the procedure being 
easily standardized among different laboratory set ups. 
 
LAMP based platforms have been developed targeting the gyrB  gene [62, 65], the rrs 
gene [66] and the IS6110 [33] useful  in TB detection. This technique has also been 








2.2. HYPOTHESIS, AIMS AND OBJECTIVES 
2.2.1. Hypothesis 
The LAMP assay is an accurate TB diagnostic tool which will improve the diagnosis 
of TB.  
2.2.2. Aims 
To determine the performance outcomes of the manual LAMP platform on single spot 
sputum collected from TB suspects at primary health care centres in Cape Town, 
South Africa vs. concentrated fluorescence smear microscopy and liquid culture for 
the diagnosis of pulmonary TB. 
2.2.3. Objectives 
 To evaluate the sensitivity and specificity of LAMP for the detection of TB vs. 
liquid culture as a reference standard. 


















2.3. MATERIALS AND METHODS 
2.3.1. Study design 
This project was embedded in a bigger multi-centre, blinded, cross-sectional study to 
determine the performance of LAMP in patients with symptoms of pulmonary TB 
(PTB) in comparison to conventional methodologies (concentrated smear microscopy 
and liquid culture). However, for this particular analysis only the Cape Town site 
specific data was used. 
2.3.2. Study flow 
TB suspects provided two sputum specimens each. A direct smear and a direct LAMP 
test were performed from each sputum sample. After NALC-NaOH decontamination, 
a concentrated smear, an LJ culture, and a MGIT culture were performed from each 
sputum sample, Figure 9. The second sputum also underwent conventional DNA 
extraction (Qiagen) from which a LAMP test was performed.  The first positive 
culture from each patient underwent confirmation of M. tuberculosis species by 
MPT64 antigen detection.  
 





Definition of abbreviations. LJ=Lowenstein Jensen, MGIT=Mycobacterial growth 
indicator tube, NALC-NaOH= N-acetyl-L-cystein-NaOH. * Confirmation of MTB in 
all positive cultures with Capilia rapid test or conventional methods. 87 patients were 
culture-positive, 59 patients were smear-positive and 85 were LAMP-positive. 
 
2.3.3. Sample size 
In total, 301 patients with suspicion of PTB were enrolled. 
 
2.3.4. Inclusion and exclusion criteria 
2.3.4.1. Inclusion criteria 
 Persistent cough (>2 weeks) and at least one other typical symptom of PTB 
(fever, night sweats, malaise, recent weight loss, contact with active case, 
hemoptysis, chest pain, loss of appetite) 
 Provision of written and signed informed consent. 
 Patient aged 18 years or above. 
 Patients able to provide two expectorated sputum specimens (2 sputum 
specimens of ≥1.5 ml each) over the course of 2 days. 
2.3.4.2. Exclusion criteria 
 Patients receiving any anti-TB medication, including fluoroquinolone and 
aminoglycosides in the 60 days prior to testing 
 Patients with only extra-pulmonary disease 
 Inability to provide informed consent (e.g. mentally impaired). 
 
2.3.5. Subject recruitment 
Patients who had symptoms consistent with PTB presenting to health facilities were 
asked to participate. Patients were identified by regular clinic staff or study personnel 
during an initial interview. Patients would be told that participation is voluntary and 




signed by all participating patients. Eligible patients who signed the informed consent 
form will have their medical history taken, and they will undergo a clinical 
examination, a chest X-ray, HIV testing (only if part of the routine standard of care), 
and they will be asked to provide two sputum samples (see Figure 9). Samples had to 
be collected before the patient starts TB treatment. All results were recorded in the 
Case Report Form (CRF). Study participants with incomplete CRFs were withdrawn 
and a new study subject enrolled instead. Statistical analysis was done using a 
statistical software; OpenEpi (Open Source Epidemiologic Statistics for Public 
Health, Version 2.3. www.OpenEpi.com) and Graphpad Prism (version 5). 
 
2.3.6. Laboratory based methods 
 
2.3.6.1. Sputum sample Preparation (10 - 20 min) 
60 µL of sputum was transferred from a sputum cup to a heating tube, using an Eiken 
disposable micropipette. The heating tube was inverted 3-4 times and placed in the 
heating block at 90°C for 5 min to lyse and inactivate the mycobacteria. The heating 
tube was removed from the heating block and allowed to cool down for 2 minutes and 
immediately after that attached to an absorbent tube and contents shaken until all the 
powder had dissolved. An injection cap was then attached on the heating tube and 
tightly screwed to pierce the seal, Figure 10. 
 
2.3.6.2. Reaction Tube Preparation (5-15 min) 
The heating tube’s nozzle was inserted into a reaction tube and 30-35 µl of DNA 
solution was transferred. The reaction tubes were flicked down to collect the DNA 
solution in the cap and allowed to stand for 2 min before inverting the tubes upright 





2.3.6.3. Amplification (45 min) 
The incubators temperature was set at 67°C.Reaction tubes were loaded into the 
heating block and amplification started through switching on the machine. 
Amplification was stopped automatically after a 5 min inactivation step. 
 
2.3.6.4. Visual readout 
The reaction tubes were placed in the UV reader integrated into the heating block and 
the results were recorded. Reaction tubes were stored without opening the vials to 




90 C for 5 
min
LAMP reaction
at 67℃ for 40 min
Collect 60 µl of raw 




(fluorescence signal = TB pos)
Close caps, flick 
down tubes and 
allow to stand 
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Figure 10: TB Loopamp™ procedure showing the consumables, tubes and standard 






2.3.6.5. Definitions applied for the analysis 
The diagnosis of individuals was based on the detailed characterization criterion done 
by a clinician blinded to the assay results. Definite TB; a clinical presentation 
compatible with TB having at least one spot sputum sample culture-positive for M. 
tuberculosis (culture-positive TB), Non-TB; no bacteriologic evidence of TB based 
on smear microscopy and culture and when available no radiologic evidence to 
support the diagnosis of TB and Indeterminate TB; where either the culture or chest 
x-ray results (or both) were unavailable, and or the patient was lost to follow-up or 
transferred to another centre, making it impossible to confidently rule-out or rule-in 

































# of TB suspects 297 58 29  
Median Age (IQR) 35 (28-44.3) 35 (28-44.1) 35 (28-44.2) 0.114 
Males 179 (60) 40 (69) 17 (59) 0.352 
Females 118 (40) 18 (31) 12 (41) 0.352 
HIV-positive 
patients+ 
108 (36) 18 (31) 19 (66) 0.003 











Chest X ray 
compatible TB likely 
patients 
95 (32) 50 (86) 16 (55) 0.002 
Definitions of abbreviations: TB; tuberculosis 
* P value comparisons are for smear-positive, culture-positive vs. Smear-
negative, culture-positive   groupings. 
+ Excludes 39 patients who refused HIV testing and or with no data recorded. 
≠ Excludes 18 patients who were HIV-positive but with no CD4 count data. 
 
Figure 11 depicts how patients were categorised and placed into different diagnostic 
sub-groupings. 297 patients with suspected TB were eligible for inclusion into the 
analysis (Figure 11). The patient demographic and clinical characteristics are shown 
in Table 5. A total 87 (29 %) of the 297 patients had definite TB. Of these, 58 (67%) 




smear-negative, culture-positive TB, Table 5. A total 60 (20 %) patients were 
classified as probable TB, whereas 150 (50%) patients were classified as non-TB. 
 
Figure 11: Flow diagram outlining patient enrolment, diagnostic category including 
HIV status in patients within primary health care facilities in Cape Town, South 
Africa used for the analysis. 
 
 
2.4.1. Diagnostic accuracy of LAMP on sputum 
Of the 87 culture-positive patients, 67 had LAMP-positive sputum. The sensitivity of 




same sputum, which had a sensitivity of [67% (56 - 76%); p=0.134; Table 6]. 18 of 
the 202 culture-negative patients had LAMP-positive sputa, resulting in a specificity 
of 91% (86 - 94%) which was significantly different to smear microscopy [99% (97 - 
99%); p<0.003]. The positive predictive value (PPV) of LAMP was 79% (69 - 86%; 
67/85) which was significantly different to smear microscopy which had a PPV of 
[98% (91-99%; 58/59; p<0.003; Table 6], while there was no difference in the NPV 
of the LAMP test and smear microscopy [(90% vs. 87%); p=0.363; respectively, 
Table 6]. 
2.4.2. Effect of HIV co-infection on LAMP performance 
HIV co-infection did not impact on the sensitivity and specificity of LAMP. The 
LAMP test sensitivity in HIV-infected patients [70% (54 - 82%); p=0.162] was 
similar in its performance in HIV-uninfected patients, 85% (69 - 93%), while also 
having similar specificity [91% (81 - 96%); in HIV-infected patients] compared to a 
specificity of [89% (82 - 93%); p=0.702, in HIV-uninfected patients]. The specificity 
of LAMP in HIV-uninfected patients was 89% (82 - 93%) which was different to 
smear microscopy performed on the same sputa, [100% (96 - 100%); p=0.0001], 
while also the NPV of LAMP was not the same as that of  concentrated smear 
microscopy [85% (76 - 91%) vs. 95% (89 - 98%); p=0.001; respectively, Table 6]. 
2.4.3. Accuracy of the LAMP assay in smear-negative individuals 
The sensitivity of the LAMP test in smear-negative individuals was 40% (23- 59%) 
which was significantly different from LAMP performed on the same sputum, which 
had a sensitivity of [77% (67 - 84%); p<0.0000001, Table 6]. HIV co-infection didn’t 
impact on the sensitivity and specificity of the LAMP assay in smear-negative cases, 
whereas it had a significant influence in NPV between HIV-infected and -uninfected 








Table 6.Diagnostic accuracy of LAMP performed on spot sputa and stratified by HIV 
status. (Liquid culture positivity for Mycobacterium tuberculosis serves as a reference 
standard). 











































































LAMP performed in smear-































































67/86   
(p=0.0008)+ 


























62/73   
(p=0.023)+ 
(P=0.269)ƚ 
LAMP performed in smear-
















Definition of abbreviations: CI= confidence interval; NPV= negative predictive 
value; PPV= positive predictive value.    
*Excludes 39 patients who refused testing and or with no data. 
¥ Specificity calculations were based on culture-negative samples obtained from 
culture- negative group (non-TB). 
⁺P-values marked with a ⁺ are for comparisons according to HIV-status. 
† P-values marked with a † are for comparisons between LAMP and smear 
microscopy 
‡ P-values marked with a ‡ are for comparisons between LAMP and LAMP 
performed in smear-negative patients 
 
 
2.4.4. Diagnostic accuracy of LAMP 
Overall, LAMP had a sensitivity of 70% (54 - 83%) equivalent to the overall sensitivity 
of sputum smear microscopy [49% (33 - 64%), p=0.064; Table 7]. LAMP sensitivity was 
similar in patients with CD4<200 cells/ml vs. CD4≥200 cells/ml [67% (82 - 96%) vs. 
65% (41 - 83%); p=0.937, respectively]. In smear-negative patients, the sensitivity of 
LAMP was 44% (23 - 67%). The specificity of LAMP was 91% (82 - 96%) which was 
similar to smear microscopy [99% (92 - 99%); p=0.064]. The PPV of LAMP was similar 
to smear microscopy [81% (65 - 91%) vs. 95% (75 - 99%); p=0.207, respectively, Table 












183/198   
(p=0.436)≠ 
 
0 100/100  
(p=0.034)≠ 
7/13   
(p=0.082)≠ 






Table 7. Performance outcomes of LAMP for the detection of MTB in persons 
infected with HIV, stratified by CD4 count. (Liquid culture positivity for 
Mycobacterium tuberculosis serves as a reference standard). 
 HIV-infected patients 
n=108* 
 
Patients infected with 
HIV with CD4 count < 
200 cells/ml + 
n=31 
Patients infected with 
HIV with CD4 count ≥ 





























































LAMP performed in smear-























































































Definition of abbreviations: CI; confidence interval, NPV; negative predictive 
value; PPV; positive predictive value.    
*Excludes 21 HIV-positive patients with no CD4 count data.  
⁺P-values marked with a ⁺ are for comparisons according to HIV-status. 
† P-values marked with a † are for comparisons between LAMP and smear 
microscopy 
‡ P-values marked with a ‡ are for comparisons between LAMP and LAMP 
performed in smear-negative patients 
 
 
2.4.5. Culture time to positivity and LAMP performance 
The graph, Figure 12, shows that as time to culture positivity increases, LAMP 
sensitivity decreases. LAMP-positivity had a significant shorter time to culture-
positivity than LAMP-negative patients , where, the mean time to detection (IQR) for 
LAMP-positive patients was 16 days (4-50), while in LAMP-negative patients it was 
40 days ( 6-50); p<0.0001. 
LAMP performed in smear-































Figure 12: Graph showing culture time to positivity in patients who are LAMP-
positive or -negative. 
 
2.5. DISCUSSION 
This study evaluated the LAMP diagnostic accuracy in a high prevalence setting. The 
key findings were that 
i. The LAMP assay had modest sensitivity. 
ii. LAMP performed modestly in HIV-infected individuals as compared to smear 
microscopy. 
iii. LAMP has an incremental yield over smear microscopy. 
With the existence of smear-negative TB and HIV co-infection in high HIV prevalent 
settings, sensitive NAATs such as LAMP can be used to diagnose TB suspects. In our 
study, the sensitivity in smear-negative cases was 48 % (32.4 - 65.7%; 14 of 29), 
which is similar with an evaluation study by Boehme et al. [65] of the LAMP 
prototype targeting the gyrB gene which had a sensitivity of 48.8% in smear-negative, 




In a study by Pandey et al. [66], in Nepalese patients, their in-house LAMP assay had 
a sensitivity of 100% (96/96) while having a specificity of 94.2% (98/104). In our 
study, we observed different sensitivity having a sensitivity of 70%, but similar 
specificity of 91% to their findings.  In India, [88] their LAMP assay showed a 
sensitivity of 44% and specificity of 94.4% which was way below our findings where 
we had sensitivity of 70%, however when they prolonged the incubation period to 90 
minutes and 120 minutes, they experienced improved sensitivities (85.7% and 91.7%; 
respectively), and specificities of 93.9% and 90.9% respectively. 
Notably, in a study by Nagdev et al. [89], in India, they showed a high sensitivity 
(88.23%) of their LAMP assay targeting the insertion sequence 6110 when diagnosing 
TBM using CSF which might otherwise show that LAMP performance in non sputum 
samples may perform better though further research is still needed to ascertain this. 
However, in these comparison studies [65, 66, 89, 90], the gold standard was culture 
positivity, similar to our reference standard in our study,  whereas Nagdev et al. [89], 
had an additional reference that of clinical features such as sub-acute or chronic fever 
and signs of meningeal irritation for TBM positivity in addition to culture positivity. 
Amplicor (Roche Diagnostics, Basel Switzerland) which has a sensitivity of 92% in 
smear-positive, culture-positive specimens and 60% in smear-negative specimens 
shows considerable advantage over LAMP (77% and 48% respectively) but the only 
problem with this application is of infrastructure constraints, need for PCR space and 
the time period of at least 7 days taken until results are out especially in a high burden 
set up like where our research was conducted [91]. 
Also comparing LAMP with Xpert MTB/RIF and MTBDRplus, it has been observed 
that Xpert MTB/RIF has a greater sensitivity of 98.2% in smear-positive specimens, 
and 75.2% in smear-negative patients in a multi-country study by Boehme and 
colleagues [44], with 76% observed with the MTBDRplus assay amongst smear-
positive, culture-positive patients in one study by Scott and colleagues [20]. Other 
studies have reported sensitivities of NAAT’s between 69% to 85% in extra-
pulmonary specimens [52]. However, the Xpert MTB/RIF system given its high 
operational costs and cold chain storage requirements for cartridges and Xpert buffers 
especially within high burdened resource limited set ups might face limited 




for sample (sputum) liquefaction, genomic DNA extraction, target amplification and 
amplicon detection, which eventually means that there is need for numerous steps, 
different work stations and increased risk of contamination with genomic bacterial 
DNA or amplicons generated [65]. The limitations for the comparison studies are that 
the test was not evaluated in smear-negative TB cases, which is an important group of 
patients while also repeated power supply and cold chain interruptions could have 
adversely impacted on the test’s performance [65]. Important to note is the fact that 
the clinical follow-up of LAMP-positive, culture-negative patients was not done 
which could have allowed evaluation of the test’s false-positive error rate [65]. The 
study by Pandey et al. [66] showed that the number of culture-positive and smear-
negative samples was not large enough to strongly conclude superiority of the test to 
smear and comparable sensitivity to culture. 
Inhibition might have been a reason for our study to have such modest sensitivity 
probably as a result of specimen morphological characteristics such as viscosity of 
sputum samples and whether the sample was bloody, which can impact on 
liquefaction and extraction protocols of the assay which we didn’t assess which might 
affect the performance of the test. 
The general observation of low specificity (Table 6 and Table 7), might probably be 
as a result of general cross contamination caused by lack of proper cleaning, and 
disposition of contaminated reagents and or surfaces which has to be strictly adhered 
to in order to get rid of amplicons. Also technical issues like defective heating tubes 
and absorbent tubes can ultimately influence such problems of low specificity.  
This particular study had a limited sample size as only the Cape Town site specific 
data was used for analysis, while also sampling bias could have ensured as a result of 
the difficulty in comparison between subgroups.  
However, some of the limitations of the LAMP test are that it has poor sensitivity 
with paucibacillary specimens such as smear-negative and extra pulmonary samples. 
This is complicated by the mycobacterial cell wall physiology which makes it difficult 
to extract DNA from cells while the assay also has the disadvantage of being unable 
to detect drug resistance. 
Overall, use of the LAMP test is feasible as a NAAT that allows direct identification 




high specificity and modest sensitivity, it can lead to the identification of M. 
tuberculosis in smear-positive individuals, and also confirmation of diagnosis in 
suspected smear- negative TB cases. 
Conclusion 
LAMP modestly out performed smear microscopy and can rapidly increase the case 
detection of TB in developing countries. The LAMP assay appears to be a promising 
rule-in test, with a specificity of 91%, when using sputum from patients with 
suspected TB. However, although the sensitivity (70%) is higher than that of smear 
microscopy, the LAMP assay in this study did not have incremental value over smear 
(difference between the sensitivities was not statistically significant). It should be 
emphasized that the test isn’t ready for use yet given the high false positive error rate 
(specificity < 95%), while these are preliminary data, further development maybe 
required on the stability and sensitivity of LAMP for its application in clinical 


















3. CHAPTER 3 
 
 THE DIAGNOSTIC ACCURACY OF XPERT MTB/RIF PERFORMED 
ON NON-SPUTUM SPECIMENS FROM PATIENTS SUSPECTED OF TB. 
 
3.1. Xpert MTB/RIF performance using bronchoalveolar lavage fluid (BALF) 




Current tools for TB diagnosis pose several challenges such as suboptimal accuracy, 
slow test turn-around time especially at point-of-care, and lack of simplicity, and ease 
of operation. Smear-negative and sputum-scarce TB coupled with HIV co-infection 
further compromises the accuracy of existing tools. This study evaluated the 
diagnostic accuracy of Xpert MTB/RIF on broncho-alveolar lavage fluid (BALF) 
collected from South African patients. 
Methods 
152 patients who were sputum scarce or smear-negative were recruited into the study. 
1 ml of the BALF aliquot or a re-suspended pellet from 10 ml of the broncho-alveolar 
lavage fluid obtained from each patient was used for Xpert testing. Liquid culture was 
performed on BALF collected at the same time as that used for Xpert testing, where 
liquid culture served as a reference standard for definite TB. We evaluated accuracy 
according to HIV and smear microscopy status, when these data were available. Also, 
the relationship between Xpert performance and culture time to positivity (TTP) was 
compared. 
Results 
27 of 152 patients were culture-confirmed for M. tuberculosis. Of the definite TB 
patients, Xpert significantly outperformed smear microscopy (93%; 95% CI 77 - 98% 




though not significant, slightly increased Xpert sensitivity to 95% (75 - 99%). The 
time to culture-positivity (TTP) was significantly influenced by the HIV-status of 
patients with mean TTP values (23.58 vs. 21.48 days; p=0.02), while there was no 
correlation between Xpert MTB/RIF generated cycle threshold values (CT) and TTP, 
p=0.09. 
Conclusion 
Xpert MTB/RIF significantly outperformed smear microscopy on BALF and has 
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The current methods of diagnosing TB such as smear microscopy and or cultures 
either have poor sensitivity or are time consuming, which has adverse effects on 
patient treatment outcomes. However, obtaining a high quality biological specimen 
for testing is paramount to reducing the diagnostic delay [57]. 
Sputum scarce TB, smear-negative TB and the difficulty associated with diagnosing 
extrapulmonary tuberculosis (EPTB), all mean that other biological fluids other than 
sputum should be evaluated in determining the diagnostic accuracy of NAATs 
especially in TB endemic areas.  
Smear-negative TB disease increases morbidity and mortality and in cases of HIV co-
infection, smear microscopy becomes problematic as it misses a considerable number 
of cases. For example, Behr et al, found that approximately 17% of TB transmission 
is as a result of smear-negative TB cases [92]. Also important to note is the fact that 
acid-fast bacilli smear microscopy for detecting TB is limited by the need for 5000-
10000 bacilli per millilitre [93]. In a study in Vietnam by Nhu et al [94], smear 
microscopy performed in patients with suspected TB-meningitis on CSF had a 
sensitivity of 79% (72 - 84%; 143/182). This necessitates the need for improved point 
of care diagnosis, which is accurate and rapid. 
 Bronchoscopy with BALF or bronchial washings is often performed in patients who 
are smear- negative and or sputum scarce as this group of patients represents up to a 
third of those with pulmonary TB [57]. Xpert MTB/RIF has an improved diagnostic 
accuracy over smear microscopy [44], while it still has a detection deficit in smear-
negative and HIV-infected patients [95]. 
There are limited published studies which evaluated Xpert MTB/RIF assay’s 
performance on BALF [54, 96]. We prospectively evaluated the accuracy of Xpert 
MTB/RIF performed on BALF obtained from smear-negative or sputum scarce 







3.1.2. HYPOTHESIS, AIMS AND OBJECTIVES 
Hypothesis 
The Xpert MTB/RIF is an accurate point of care TB diagnostic tool using BALF as a 
biological sample which will improve diagnosis in smear-negative and or sputum 
scarce TB patients. 
Aims 
To determine the performance outcomes of Xpert MTB/RIF on BALF from TB 
suspects at a hospital in Cape Town, South Africa vs. smear microscopy and liquid 
culture techniques for the diagnosis of pulmonary TB. 
Objective 
 To determine the diagnostic accuracy of Xpert MTB/RIF in smear-negative 
and -positive patients. 

















3.1.3. MATERIALS AND METHODS 
3.1.3.1. Study design 
This study was prospectively carried out to determine the performance of Xpert 
MTB/RIF in patients with symptoms of pulmonary TB who were referred to the 
respiratory clinic at Groote Schuur hospital in Cape Town, South Africa. Initially the 
project included the collection of BALF which was frozen at -20°C for later testing, 
which was designated phase 1 and was for research purposes only. Treatment was 
guided by smear microscopy and culture results in phase 1. Phase 2 included 
collection of this BALF sample which was used immediately for Xpert MTB/RIF 
testing and in this phase used for guiding treatment in patients. 
3.1.3.2. Study Flow 
Detailed patient and laboratory specific information was recorded and patients 
underwent HIV testing upon counselling. An aliquot of BALF was either frozen at -
20°C for later batched testing in phase one, or used immediately for MTB/RIF testing 
in phase two. Patients were classified as definite TB if they had at least one specimen 
culture- positive for TB or upon histological investigation of the transbronchial biopsy 
were reported to contain caseating or necrotising granulomatous inflammation 
consistent with TB [57], while those patients with BALF which was culture-negative 
for TB and the absence of histological evidence of active TB disease were classified 
as probable TB ,if initiated on anti-TB treatment. Empirical treatment of a patient was 





Figure 13: Study flow diagram showing the patients included in the analysis and test 
results. 
Definition of abbreviations. BALF, bronchoalveolar lavage fluid; PBS, phosphate 
buffer saline. 
*All patients provided BALF. Bronchial brushings and biopsies were provided at the 
discretion of the attending clinician to the reference laboratory. Smear and culture 
were performed on these latter two specimens when possible by the reference 
laboratory. 
+MTB/RIF was performed on fresh BALF from 74 patients. Fluid thawed from a 
frozen specimen was used for MTB/RIF for 78 patients recruited prior to the WHO 
endorsement of Xpert MTB/RIF. 
#Histology was considered compatible with active TB if necrotising or caseating 
granulomatous inflammation were observed by the reference laboratory. Eleven 
individuals had record of histology information missing 
 
3.1.3.3. Sample size 






3.1.3.4. Inclusion criteria 
Patients above 18 years of age were recruited. Patients should have had at least one 
symptom of TB, a chest radiograph with infiltrates compatible with active TB and or 
at least two consecutive sputum smear microscopy results negative for AFB(within 
two weeks of enrolment) and or were unable to self-expectorate  sputum. 
 
3.1.3.5. Subject Recruitment 
Patients who had symptoms consistent with PTB presenting to the hospital were asked 
to participate. Patients were told that participation was voluntary and that they had the 
opportunity to ask questions individually. A consent form was signed by all 
participating patients. Eligible patients who signed the informed consent form had 
their medical history taken, and underwent a clinical examination, HIV testing and 
bronchoscopy after referral.   . Samples were collected before the patient started TB 
treatment. All results were recorded in the Case Report Form (CRF), which was 
entered into an electronic database. Study participants with incomplete CRF’s were 
withdrawn from the study and new study subjects enrolled instead. Statistical analysis 
was done using a statistical software; OpenEpi (Open Source Epidemiologic Statistics 
for Public Health, Version 2.3. www.OpenEpi.com) and Graphpad Prism (version 5). 
 
3.1.3.6. Laboratory Based Methods 
Bronchoscopy was carried out by trained pulmonologists. BALF collected was split 
and one aliquot sent immediately to Groote Schuur Hospital for NaLC-NaOH 
decontamination, and the second aliquot was used for MTB/RIF testing. The 
decontaminated specimen was examined twice by concentrated fluorescence smear 
microscopy and liquid culture for MTB using BACTEC MGIT 960 System (BD 
Diagnostics, USA) [97]. Culture-positive isolates underwent routine phenotypic drug 
susceptibility testing for rifampicin and isoniazid using the MGIT 960 SIRE kit. Upon 
request, concentrated fluorescence smear microscopy and liquid culture were also 
performed on bronchial washings and transbronchial biopsy specimens (where 
transbronchial biopsies underwent histological examination if available) [57]. The 




was decanted, and the pellet re-suspended in 1 ml of sterile phosphate- buffered saline 
(PBS) and Xpert MTB/RIF procedure was then followed as described [47, 98], with 
the laboratory technician performing the procedure blinded to patient information and 

























3.1.4.1. Study population and TB Diagnoses 
160 patients with suspected pulmonary TB who were referred for bronchoscopy 
consented to participate in the study and were recruited with eight patients being 
excluded from the analysis (Figure 13). Of the 152 included patients, 110 (72%) were 
sputum-scarce and 44 (29%) were HIV- infected (Table 8).  27 of the 152 patients 
(18%) were BALF culture-positive for M. tuberculosis. When a bronchial brushing or 
transbronchial biopsy was cultured, 9 out of 38 patients (24%) and 4 out of 15 (27%) 
of patients were positive respectively. However, all culture-positive bronchial 
brushings and or transbronchial biopsies had culture-positive BALF. Transbronchial 
biopsies histological examination revealed active TB compatibility in 7 of 102 cases 
(7%) that were examined, with one patient having culture-negative BALF. 














Median age in yrs 46.1 41.4 45.9 0.418 
Male (%) 82 (54) 10 (37) 72 (57) 0.621 
Female (%) 70 (46) 17 (63) 53 (42) 0.057 
Sputum - scarce (%) 110 (72) 19 (70) 91 (73) 0.788 
HIV infected* 44 (29) 8 (30) 36 (29) 0.918 
Median CD4 count 
(cells/µl) (IQR) if 
HIV infected ƚ 
165 (67-406) 151 (58-665) 179 (67-406) 0.698 
Previous TB 
treatment≠ (%) 
50 (33) 5 (19) 45 (36) 0.078 
Smoker (past or 
current) α (%) 
41 (27) 5 (19) 36 (29) 0.287 





ƚTen patients with HIV infection were missing CD4 count data. 
≠six patients were missing previous TB data. 
αTwelve patients were missing smoking data. 
BALF, bronchoalveolar lavage fluid; TB, tuberculosis 




3.1.4.2 Diagnostic accuracy of Xpert MTB/RIF performed on BALF 
Of the 27 definite TB (culture-positive) patients in our cohort, 25 had Xpert-positive 
BALF. Xpert had a sensitivity of 93% (25/27; 77 - 98%) which was significantly 
higher than smear microscopy performed on the same BALF, 58% (15/26; 39- 74.5%; 
p<0.004; Table 9). 5 of the 127 non-TB cases (culture-negative) had Xpert-positive 
BALF having a specificity of 96% (120/125, 91- 98%) similar to smear microscopy 
which had, 99.2%  (124/125; 96 - 99%; p=0.121).  The positive predictive value 
(PPV) of Xpert was 83% (64 - 93%; 25/30) which was similar to that of smear 
microscopy, 94% (72 - 99%; 15/16; p=0.370; Table 9), while their (Xpert MTB/RIF 
and smear microscopy) negative predictive values (NPV) were not similar [98% (94 -
100%; p=0.018) vs. 92% (86 - 95%), respectively, Table 9].  
3.1.4.2. Impact of BALF processing on Xpert MTB/RIF performance  
In this cohort, 98 patients had BALF available for centrifugation, where 19 patients 
were culture-positive for TB. We found that centrifugation resulted in a slight 
increase in Xpert MTB/RIF sensitivity, 95% (75 - 99%). Also centrifugation of BALF 
increased Xpert MTB/RIF sensitivity in HIV-infected patients having sensitivity of 
100% (3/3; 44% - 100%), whereas for uncentrifuged BALF the sensitivity was 75% 
(6/8; 41% - 93%). However, it should be noted that this increase in sensitivity was not 
significant (i.e. 100% vs. 75%; p=0.509). 
3.1.4.3. Accuracy of Xpert MTB/RIF in HIV co-infected patients 
Xpert had a significant increase in sensitivity of 100% (12/12, 76 - 100%, p=0.018) in 
HIV-uninfected individuals vs. smear microscopy, 58% (7/12; 32 - 81%), whereas in 
HIV-infected patients, the assay had modest sensitivity of 75% (6/8; 41 - 93%; Table 




vs. 75%; p=0.147) when performed in these particular cluster of patients (HIV-
infected and uninfected patients). 
3.1.4.4. Xpert MTB/RIF performance in smear-negative cases 
It should be noted that Xpert MTB/RIF had a sensitivity of 82% (52 - 95%), while it 
also retained a higher specificity of 97%. In HIV-uninfected patients who were smear-
negative for TB, the assay had 100% sensitivity (57-100%), and sensitivity dropped to 























Table 9.Accuracy of Xpert MTB/RIF performed on BALF and stratified by HIV 
status of patients. (Liquid culture positivity for M tuberculosis serves a reference 
standard). 
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MTB/RIF performed on a 
re-suspended pellet 






































































+Based on TB prevalences of 18%, 14% and 18% overall and in patient groups 
with HIV infection and without infection. BALF, bronchoalveolar lavage fluid; 
NPV, negative predictive value; PPV, positive predictive value; TB, tuberculosis. 
+P-values marked with a+ are for comparisons according to HIV-status. 
ƚP-values marked with aƚ are for comparisons between Xpert MTB/RIF and 
smear microscopy. 
≠P-values marked with a≠ are for comparisons between Xpert MTB/RIF and 
Xpert performed in smear-negative patients. 
βP-values marked with aβ are for comparisons between Xpert MTB/RIF 
centrifuged and Xpert MTB/RIF uncentrifuged. 
 
 
3.1.4.5. Diagnostic accuracy of Xpert MTB/RIF performed on uncentrifuged 
BALF stratified by the CD4 counts of patients 
In this cohort, of the eight definite TB cases (culture-positive), six had Xpert-positive 
BALF. Xpert MTB/RIF test had a sensitivity of 75% (41 - 93%; 6/8), which was 
similar to smear microscopy performed on the same BALF, 57% (25- 84%; p=0.527), 
table 3.3. Two of the thirty-six non TB cases had Xpert -positive BALF resulting in 
specificity of 94% (82 - 99%); which was similar to smear microscopy [97%; (86 -
100%; p= 0.62), Table 10]. The PPV and NPV of Xpert were 75% (41 - 93%) and 
94% (82 - 94%), respectively. 
MTB/RIF performed on 
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3.1.4.6. Effect of BALF centrifugation on Xpert MTB/RIF performance in 
HIV-infected patients stratified by CD4 counts 
Centrifugation of the BALF resulted in Xpert having a sensitivity of 100% (68- 
100%) in patients with CD4 counts less than 200 cells/ml, compared to 73% (43-90%; 
p=0.170, Table 10) in patients with CD4 counts greater than or equal to 200 cells/ml. 
 
Table 10.Performance outcomes of Xpert MTB/RIF on BALF for the detection of 
MTB in persons infected with HIV, stratified by CD4 count. (Liquid culture positivity 
for Mycobacterium tuberculosis serves as a reference standard). 
 HIV-infected patients 
n=44 
 
Patients infected with 
HIV with CD4 count < 
200 cells/ml 
n=18 
Patients infected with 
HIV with CD4 count ≥ 
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MTB/RIF performed on a 
re-suspended pellet 




































+Based on TB prevalences of 18%, 14% and 18% overall and in patient groups 
with HIV infection and without infection. BALF, bronchoalveolar lavage fluid; 
CI, confidence interval; NPV, negative predictive value; PPV, positive predictive 
value; TB, tuberculosis. 
+P-values marked with a+ are for comparisons according to HIV-status. 
ƚP-values marked with aƚ are for comparisons between Xpert MTB/RIF and 
smear microscopy. 
≠P-values marked with a≠ are for comparisons between Xpert MTB/RIF and 
Xpert performed in smear-negative patients. 
βP-values marked with aβ are for comparisons between Xpert MTB/RIF 
centrifuged and Xpert MTB/RIF uncentrifuged. 
 
 
3.1.4.7. Markers of bacterial load (TTP’s),HIV status and Xpert MTB/RIF 
performance 
Xpert MTB/RIF-positivity and -negativity was similar to liquid culture time to 
positivity.  The mean time to detection (IQR) for Xpert MTB/RIF-positivity was 20 
days (0-49), whereas for Xpert MTB/RIF-negativity was [17 days (0-36); p=0.8997, 
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Figure 14]. HIV-positivity of patients significantly influenced liquid culture time to 
positivity; with HIV-positivity having mean time to detection (IQR) [23 days (0-42)]; 
















































































Figure 15: Comparison of time to culture positivity in HIV-infected and -uninfected 
patients. 
 
3.1.4.8. Relationship of Xpert MTB/RIF-generated CT (cycle threshold) values 
with bacterial load  
There was no correlation between Xpert MTB/RIF-generated CT values and TTP; 























Figure 16: Correlation of BALF Xpert MTB/RIF cycle threshold values and 



















Studies showing the accuracy of Xpert on BALF are limited, and the impact of factors 
such as biological specimen processing, and HIV co-infection is unknown. The key 
findings of this study were that Xpert MTB/RIF significantly outperformed smear 
microscopy using BALF, while BALF centrifugation did not improve the diagnostic 
accuracy of Xpert MTB/RIF. 
Information regarding Xpert MTB/RIF assay performance on non-sputum samples is 
emerging, though not extensively and sufficiently studied in high HIV-prevalent 
settings [99].  It has been noted that studies examining Xpert MTB/RIF performance 
in BALF [49, 96, 100-102] have been conducted; however, due to limited numbers of 
specimens, and the decreased number of TB cases, such information is limited.  
In our study with a patient cohort of 152 patients, Xpert MTB/RIF sensitivity was 
94%, having similar sensitivities to other respiratory specimens, such as in a study by 
Teo et al. [103], Xpert MTB/RIF sensitivity was found to be 90% (80- 96%). In 
another study in France [49], the test exhibited a sensitivity of 100% in smear- 
positive specimens irrespective of the site where the clinical specimen was obtained. 
In a similar study, Miller et al. [100] showed that the test had 100% sensitivity in 
smear-positive, culture-positive pulmonary specimens.  Similarly, in a study in 
Turkey, Zeka et al. [104], showed that Xpert MTB/RIF test with smear-and culture-
positive pulmonary specimens was 100% with a specificity of 98.3. Thus it can be 
concluded herein that our study findings are in accordance with prior published data 
signifying Xpert MTB/RIF performance in diagnosing sputum scarce or smear-
negative TB patients. 
The predominantly high sensitivities earlier mentioned, are markedly exceeding 
sensitivities reported for commercially available NAAT’s. A study by Davis et al. 
[96], in Uganda, reported a sensitivity of 39% (28- 51%) and a specificity of 95% 
exhibited by the MTD test when mycobacterial culture was used as a reference 
standard. In a study in France, by Simonnet et al. [101], they reported sensitivity of 
100% in respiratory specimens and a specificity of 100% using the EMEQ 
(easyMAG/easyQ, bioMérieux, France) assay. Chou et al. [102], in Taiwan, showed 
that the Gen-Probe AMTD test had a sensitivity and specificity of 80% and 97.5% 




In our study we found that five patients were Xpert MTB/RIF-positive but having 
culture-negative results, while four were smear-negative and one smear-positive in 
this group of Xpert MTB/RIF-positive patients. The markedly increased sensitivity, 
93%  of Xpert MTB/RIF on BALF in our study, was similar to a study on the 
performance of Xpert MTB/RIF system on sputum samples which Xpert MTB/RIF 
has been optimized for in definite TB patients having 90% sensitivity [44].  
In one study it was shown that centrifugation of urine improved the diagnostic yield 
when Xpert MTB/RIF test was used in HIV-infected, sputum scarce patients with 
CD4 counts less than or equal to 200 cells/ml [36]. However, the same was not found 
to be consistent in our study when BALF was used, as we did not find a significant 
improvement in sensitivity when a similar volume of BALF was used.  
We have also shown that Xpert MTB/RIF test had reduced or rather somewhat 
modest sensitivity of 75% in HIV-infected individuals. This might be attributable to 
the findings in one study that HIV infection is associated with a decreased likelihood 
of a positive Xpert MTB/RIF result in pulmonary specimens [99]. This is also in 
accordance with our study findings where Xpert MTB/RIF test results were not 
influenced by the bacterial burden of the specimen probably due to the decreased 
bacillary load in the lungs of HIV co-infected patients with PTB due to the lower 
frequency of cavitation in these patients [99]. 
Some of the limitations of this study are that we did not look at the use of induced 
sputum on the performance of Xpert which might influence the need for not using the 
assay in sputum scarce TB patients since the procedure (bronchoscopy) is expensive 
and demands expertise which might not be necessarily available in high burdened 
resource limited settings. Our data might be mostly relevant to low burden resource-
advantaged settings experiencing an influx of migrants coming from high burdened 
set ups as such countries due to the availability of resources can afford bronchoscopy 
procedures. Another drawback to our study might be that the volume of BALF used 
might have been insufficient especially after parts of the BALF would have been sent 
for routine diagnostic testing. The number of patients involved in the study might 







Xpert MTB/RIF system on BALF has excellent performance in diagnosing sputum 


























3.2. DIAGNOSTIC ACCURACY OF XPERT MTB/RIF USING 




The Xpert MTB/RIF accuracy data using tracheal aspirates in suspected TB patients 
who are mechanically ventilated in the intensive care unit (ICU) is limited. 
Methods 
120 South African ICU patients suspected of TB were mechanically ventilated. 
Approximately 3 ml to 15 ml of tracheal aspirate secretions was collected, where 1 ml 
of the tracheal aspirate was aliquoted for Xpert testing. Liquid culture was performed 
on tracheal aspirates collected at the same time as that used for Xpert testing, where 
liquid culture served as a reference standard for definite TB. We evaluated diagnostic 
accuracy according to HIV and smear microscopy status, when these data were 
available. Also, the relationship between Xpert performance and TTP was compared. 
Results 
Of the 120 patients, only 71 had data that could be analysable. 11 of 71 patients had 
culture confirmed TB. For these culture confirmed TB cases, Xpert had a sensitivity 
of 91% (62-98%), whereas smear microscopy had a sensitivity of 55% (28-79%). The 
difference in sensitivity was not significant (91% vs. 55%, p=0.08) though the sample 
size was limited. There was no correlation between Xpert MTB/RIF generated CT 
values and liquid culture TTP; p=0.08.  
Conclusion 
Xpert MTB/RIF outcompeted smear microscopy and is a potentially useful tool for 
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The incidence of PTB in the intensive care units (ICU) is poorly studied and the 
utility of Xpert MTB/RIF using tracheal aspirates hasn’t been documented. Tools for 
the diagnosis of active TB disease include clinical suspicion, response to treatment, 
chest radiographs, staining for acid-fast bacilli (AFB), culture for mycobacteria and 
nucleic acid amplification assays [93]. The most common testing mode of TB in 
resource poor countries which are highly TB burdened is sputum smear microscopy, 
which has amongst its disadvantages having an ability to detect approximately only 
50% of all TB cases [105, 106], such that if for some other reason such undiagnosed 
cases get admitted to the ICU, it becomes apparent for a swift diagnosis and clinical 
management of such patients with the Xpert MTB/RIF system.  Smear microscopy 
also is incapable of detecting drug resistance. Culture though accurate, requires 
between  10–1,000 viable mycobacteria per mL of specimen [3] to detect M. 
tuberculosis while having sensitivity of between 80% to 93% and allowing drug 
susceptibility testing [107] avails results after several weeks impacting on patient 
treatment regimens and patient management.  
Nucleic acid amplification testing requires as few as ~10 to 16 copies of DNA or 
RNA fragments from a given sample to be sufficient to detect M. tuberculosis [108].  
Xpert MTB/RIF assay combines, amongst its added advantages, the ability to 
simultaneously detect M. tuberculosis and rifampicin resistance while it also 
generates results within a short period of time approximately 2 hrs. The many features 
of this system include sample decontamination, hands-free operation, on-board 
sample processing and ultra-sensitive hemi-nested PCR. 
Xpert MTB/RIF test was first analysed on sputum samples where its evaluation on the 
diagnostic utility of the system showed that it was simple to use and highly sensitive, 
having sensitivity of above 95% [44, 46, 47]. As a result, how the test will perform 
using non-sputum samples is unknown. Information regards Xpert MTB/RIF 
performance is being reported in different compartments [36, 56, 57]. 
Friedrich et al. [51] in their study evaluated the utility of Xpert MTB/RIF assay for 
diagnosing pleural TB using pleural fluid and biopsy specimens on 25 patients, where 




evaluation results for using Xpert MTB/RIF test, though feasible, but further research 
needs to be carried out. 
This study evaluated the accuracy of Xpert MTB/RIF using tracheal aspirates from 
mechanically ventilated patients suspected of having TB in a randomised control trial 
























3.2.2. HYPOTHESIS, AIMAND OBJECTIVES 
3.2.2.1. Hypothesis 
The Xpert MTB/RIF assay is an accurate point of care TB diagnostic tool using 
tracheal aspirates from mechanically ventilated ICU patients which leads to improved 
diagnosis in patients suspected of TB. 
3.2.2.2. Aim 
To determine the performance outcomes of Xpert MTB/RIF assay using tracheal 
aspirates from TB suspects in the ICU of Groote Schuur Hospital, Cape Town, South 
Africa vs. smear microscopy and liquid culture techniques for the diagnosis of TB. 
3.2.2.3. Objectives 
 To determine the diagnostic accuracy of Xpert MTB/RIF assay in smear-
positive and -negative patients. 















3.2.3. MATERIALS AND METHODS 
3.2.3.1. Study design 
This study was carried out as a single centre randomised controlled trial which was 
carried out to determine the performance of Xpert MTB/RIF in mechanically 
ventilated ICU patients suspected of TB recruited at Groote Schuur Hospital, Cape 
Town, South Africa. 
3.2.3.2. Sample size 
120 patients were recruited in the parent study but for this particular analysis only 71 
patients were used. Statistical analysis was done using a statistical software; OpenEpi 
(Open Source Epidemiologic Statistics for Public Health, Version 2.3. 
www.OpenEpi.com) and Graphpad Prism (version 5). 
3.2.3.3. Study flow 
Tracheal aspirates collected were processed at the Lung Infection and Immunity Unit 
Laboratory. Xpert MTB/RIF was performed on all tracheal aspirates collected, where 
a tracheal aspirate of less than 3 ml was collected, 20 mls of saline was added to the 
tracheal-bronchial tree and aspirated. Clinical and demographic data was recorded, 
while tracheal aspirates as well as blood, and urine were obtained for later Xpert 
MTB/RIF, or alternative test analysis.  
3.2.3.4. Subject recruitment 
All patients admitted to the ICU with suspected pulmonary TB were randomized to 
the conventional investigation for TB through smear microscopy and culture, and or 
Xpert MTB/RIF analysis. Baseline data (age), cormobidities (HIV status) were 
recorded. All patients were tested for HIV and this was done routinely by the 
admitting unit.  
3.2.3.5. Classification of patients 
All patients with a positive Xpert MTB/RIF or smear or culture were designated to be 
definite TB cases, while those who had negative test results for TB and improved on 




3.2.3.6. Laboratory based Methods 
Approximately 3 to 15 mls of tracheal secretions was aspirated by means of a sterile-
suction catheter attached to the endotracheal tube of the mechanically ventilated 
patient. Samples collected were sent to the laboratory for routine processing, 
including Gram stain to assess adequacy of sputum sample and smear microscopy for 
M. tuberculosis and liquid culture (MGIT 960) in all patients. Two to 10 ml of 
unprocessed tracheal aspirate was stored at -80°C for later analysis. 
3.2.3.7. Xpert MTB/RIF assay 
The GeneXpert Dx System (Cepheid, Sunnyvale, CA) is an integrated TB diagnostic 
device that performs sample processing and real-time PCR analysis in a single hands-
free step[47]. The Xpert MTB/RIF assay consists of the Xpert MTB/RIF plastic 
cartridge, containing liquid sample-processing and PCR buffers and lyophilized real-
time PCR reagents and the GeneXpert instrument, which controls intra-cartridge 
fluidics and performs real-time PCR analysis [109].The manual sample pre-treatment 
steps for the assay involves adding sample reagent buffer to tracheal aspirate samples 
in a 2:1 ratio respectively and 2 mls of this sample-reagent buffer is then transferred 
to the sample chamber of the cartridge according to manufacturer’s instructions [98]. 
The cartridge is then inserted in the GeneXpert machine and from this point onwards, 
all steps are automated. The GeneXpert machine first captures MTB bacilli from the 
tracheal aspirate sample on a filter membrane where inhibitors and non-specific 
proteins are then washed from the captured cells with the buffer and finally the 
captured, washed cells are lysed, such that the released DNA is eluted through the 
filter membrane. The DNA solution finally gets mixed with dry PCR reagents and 
thus transferred into the PCR tube for real-time PCR and detection. To eliminate test-











3.2.4.1. Patient enrolment and test results 
 
Figure 17: Study flow diagram showing the patients included in the analysis and test 
results. 
Definition of abbreviations: C+; culture-positive patients, C-; culture-negative 
patients, S+; smear-positive patients, S-; smear-negative patients, X+; Xpert 
MTB/RIF-positive patients, X-; Xpert MTB/RIF-negative patients. 
 
3.2.4.2. Study population and TB diagnoses 
71 patients suspected of pulmonary TB were recruited and consented to participate in 
the study; Figure 17. Of these 71 patients, 25 (42%) were HIV-infected (Table 11). 11 
out of the 71 patients (15%) were tracheal aspirate culture-positive while 60 of the 71 







Table 11.Demographic and clinical characteristics. 









41.5 (32-54) 28 (19-41) 38.5 (29-52)  
Male gender 
(%) 
41 (58) 7 (64) 34 (57) 0.7 
HIV-
infected*(%) 





158.5 (58-379) 90 (30-190) 158.5 (58-379)  
Previous TB 
treatment ≠ (%) 
24 (36) 3 (30) 21 (37) 0.7 
Smoker ¥ (past 
or current) (%) 
21 (32) 4 (44) 17 (30) 0.4 
*11 patients were of unknown HIV status (test refused or data missing) 
+one patient with HIV infection was missing CD4 count data 
≠4 patients were missing previous TB data 
¥6 patients were missing smoking data 
TA, tracheal aspirate; TB, tuberculosis 




3.2.4.3. Diagnostic accuracy of Xpert MTB/RIF performed on tracheal 
aspirates 
Of the 11 culture-positive TB patients in this cohort, 10 patients had Xpert MTB/RIF-
positive tracheal aspirates. Xpert MTB/RIF had a sensitivity of 91% (10/11, 62- 
98%), while smear microscopy performed on the same tracheal aspirate yielded a 




between Xpert MTB/RIF and smear microscopy (91% vs. 55%) was not significant 
(10/11 vs. 6/11, p=0.081, Table 12) respectively. 2 of the 60 non-TB patients had 
Xpert MTB/RIF-positive tracheal aspirate giving a specificity of 97% (88- 99%, 
58/60, Table 12) which was similar to smear microscopy which had a specificity of 
100% (60/60; 94- 100%; p=0.248). The positive predictive values (PPV) were similar 
for Xpert MTB/RIF and smear microscopy, 83% (10/12; 55 - 95%) and 100% (6/6; 61 
- 100%; p=0.431),respectively, while the negative predictive values (NPV)for the 
same tests were similar, 98% (58/59; 91 - 100%) and 92% (60/65; 83 - 97%; 
p=0.146,respectively, Table 12). Co-infection with HIV did not impact on Xpert 
MTB/RIF assay sensitivity and specificity (p=0.444; p=0.588, respectively) similarly 
to PPV and NPV (p=0.154; p=0.431) respectively.  
3.2.4.4. Xpert MTB/RIF performance in smear-negative cases 
Xpert MTB/RIF sensitivity in smear-negative TB patients was found to be 80% (38 - 
96%; 4/5) while it also retained a higher specificity of 97 % (89 - 99%; 58/60; Table 
12). In HIV-uninfected patients who were smear-negative for TB, the assay had 
sensitivity of 100% (21 - 100%; 1/1; p=0.667) which was not different from when 
Xpert MTB/RIF was done in HIV-infected patients having sensitivity of 50% (9 - 
91%; 1/2). 
3.2.4.5. Accuracy of the Xpert MTB/RIF in HIV co-infected patients. 
Amongst HIV-infected patients, Xpert MTB/RIF had sensitivity of 75% (30 - 95%; 
3/4), which was not significantly different when the same tracheal aspirate was 
subjected to smear microscopy yielding sensitivity of 50% (15 - 85%; 2/4; p=0.571), 
Table 12. Xpert MTB/RIF performance in HIV- uninfected patients had sensitivity of 
100% (57 - 100%; 5/5) which was not different from  Xpert MTB/RIF performed in 




Table 12.Accuracy of Xpert MTB/RIF performed on tracheal aspirate, stratified by 
the HIV status of patients. (Liquid culture-positivity for M. tb. serves as a reference 
standard). 
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Definition of abbreviations: CI, confidence interval; NPV, negative predictive 
value; PPV, positive predictive value; TA, tracheal aspirate. 
¶Excludes 11 patients (who were missing HIV results or did not have HIV data 
recorded). 
βspecificity calculations were based on culture negative samples. 
+P-values marked with a+ are for comparisons according to HIV-status. 
ƚP-values marked with aƚ are for comparisons between Xpert MTB/RIF and 
smear microscopy. 
≠P-values marked with a≠ are for comparisons between Xpert MTB/RIF and 
Xpert performed in smear-negative patients. 
 
 
3.2.4.6 Relationship of Xpert MTB/RIF-generated cycle threshold values with 
bacterial load 
There was no correlation between Xpert MTB/RIF CT values and time to positive 




















Figure 18: Correlation of tracheal aspirate Xpert MTB/RIF cycle threshold values 










Data regarding accuracy of Xpert MTB/RIF when performed on tracheal aspirates is 
limited. Parameters such as HIV-infection, specimen morphological characteristics 
and processing are unknown. More often in sputum scarce, and or smear-negative TB 
cases, sputum induction and or bronchoscopy is used especially in resource limited 
countries with the bronchoscopy being expensive and requiring specialized personnel 
such as pulmonologist to perform the procedure. The key findings of this study are as 
follows: (1) the Xpert MTB/RIF outcompeted smear microscopy, although not 
significant which can show that when empirical treatment with smear microscopy as 
the only available rapidly used test  in high TB-burdened, resource poor countries, 
Xpert MTB/RIF maybe overestimated; (2) Xpert MTB/RIF can be used as a rule out 
test in HIV-uninfected and –infected patients due to the high NPV and PPV which are 
of great importance in deciding isolation release [110, 111].  
In this study of 71 patients, the sensitivity of Xpert MTB/RIF on tracheal aspirates 
was 91%. Similarly, in a study in France, by Armand et al. [112], they reported a 
sensitivity of Xpert MTB/RIF to be 79% with respiratory specimens which is below 
our study findings; while in another study conducted in a moderate TB prevalence 
setting, Laraque et al. [113] reported that in smear-positive specimens, their NAAT 
had a sensitivity of 96%. In a study in France, the investigators reported sensitivity of 
90% using Real-time PCR in respiratory specimens, with a PPV of 100% and NPV of 
96% [114], while Marlowe et al. [115] in their study of the Xpert MTB/RIF in 
Western USA on 217 specimens, reported a sensitivity of 98% with smear-positive 
specimens. This shows that our study had the test sensitivity falling within the range 
exhibited by these commercial NAATs [113-115]. 
In a meta-analysis of commercial and in-house tests, Pai et al., showed that for 
commercial tests (n=14), they had pooled sensitivity of 56% (46 - 66%) and 
specificity of 98% (97- 99%), while in-house tests (n=35) had pooled sensitivity and 
specificity of [76% (67 - 83%); 92% (88 - 95%); respectively)] [116], which shows 
that our study findings regards sensitivity falls within the range described in their 
analyses.  
In smear-negative patients we reported sensitivity of 80% using the Xpert MTB/RIF, 




sensitivities of between 57% to 67% in other studies [112, 114]. However, this rather 
modest sensitivity in these studies, might be attributable to differences in 
decontamination processes, cross contamination, inhibition sampling error, quality of 
the reference standard and a mixture of respiratory and other specimens in studies 
[117-120]. 
We reported an additional two patients who were Xpert MTB/RIF-positive, culture-
negative and such patients have been reported to be true representatives of TB cases 
in a previous study [48]. 
Some of the limitations of this study are that we didn’t capture specimen specific 
factors such as viscosity and or appearance (bloody or not) which could possibly 
interfere with Xpert MTB/RIF assay, i.e. the viscosity of the tracheal aspirate even 
after addition of the sample buffer may not be completely homogenized and thus 
interfere with the Xpert MTB/RIF system in harvesting bacilli nucleic acid. The other 
likely parameters might be specimen processing such as centrifugation which has 
been reported in previous studies to otherwise increase sensitivity [36, 56, 57] due to 
concentration and sedimentation of the test material which we did not look at in our 
study. 
Conclusion 
The Xpert assay on tracheal aspirates is feasible, and can be used as a rule-out TB 
diagnostic test, and there is potential to increase sensitivity of the assay by optimizing 













4. CHAPTER 4 
 DIAGNOSTIC ACCURACY OF THE XPERT MTB/RIF USING 





TB-meningitis (TBM) is difficult to diagnose with the available conventional 
methods. The accuracy of Xpert when performed on cerebral spinal fluid (CSF) of 
patients suspected of TBM remains unclear. This study evaluated the accuracy of 
Xpert in diagnosing TBM. 
Methods 
In this study, 235 South African patients suspected to have TBM had lumbar puncture 
done. Approximately 15 ml of CSF was obtained and where appropriate, 1 ml of 
uncentrifuged CSF was used for Xpert testing, and or when available, 3 ml of 
centrifuged CSF was used for Xpert analysis. Liquid culture from a specimen 
collected at the same time was used as the reference standard for definite TB. For 
each diagnostic assay and fluid tested, we evaluated diagnostic accuracy according to 
HIV status and smear microscopy status, when these data were available. 
Results 
Of the 152 evaluable patients, 41 had definite TBM, 54 probable TBM and 57 non-
TBM. Of the definite TBM patients, Xpert MTB/RIF significantly outperformed 
smear microscopy having sensitivity [49% (33-64%) versus 3% (1-15%); p≤0.001, 
respectively]. In HIV-coinfected patients, centrifugation of CSF resulted in a 
significant increase in sensitivity of Xpert MTB/RIF test, 100% (68-100%; p=0.01) 
than uncentrifuged CSF, 53% (37-69%). There was no correlation between Xpert 
MTB/RIF CT values and TTP, p=0.45. 
Conclusion 
Xpert MTB/RIF has more rule-in potential for TBM diagnosis in HIV-infected 
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TB remains a significant cause of morbidity and mortality in Sub-Saharan Africa, 
especially when HIV co-infection is involved [121]. However, up to 40% of co-
infected patients have extrapulmonary tuberculosis (EPTB) while, 10% of such 
patients have TBM [122]. TBM patients require longer periods of hospitalisation, and 
in the process such patients consume and diminish quite a lot of health-care resources 
for their management [56].  
Available diagnostic platforms such as smear microscopy perform dismally in TBM, 
with one study reporting sensitivities of less than 20% [94]. Liquid culture techniques 
such as the mycobacterial growth indicator tube (MGIT; Bactec) and the 
mycobacterial drug susceptibility assay (MODS) culture aid in improved sensitivity 
over solid culture up to about a sensitivity of 60% [123]. However the time period 
(approximately 4 weeks) it takes to give back a positive result limits its use in 
confirming of disease. 
In a meta-analysis by Morgan et al. [124], line probe assays such as the INNO-LiPA 
Rif. TB kit (Innogenetics, Zwijndrecht, Belgium) had sensitivity greater than 95%, 
showing that such NAAT’s had increased diagnostic potential; however, due to their 
requirements for technical expertise, being expensive and prone to contamination, 
such a system becomes unsuitable for implementation in resource-limited settings. 
Molecular techniques such as the Cobas Amplicor MTB (Roche Diagnostics, 
Indianapolis, IN) has been widely used for the detection of M. tuberculosis in 
respiratory samples while problems have been reported particularly in non-respiratory 
samples such as the presence of inhibitor enzymes and contamination [125]. 
Sensitivity is often variable and offer little advantage over smear microscopy [126].  
Thus as a result, the current diagnostic methods are somewhat limited in sensitivity 
and applicability, while also due to the paucibacillary nature of TBM and the 
requirement for larger volumes of CSF that are rather difficult to obtain in cases of 
children makes such techniques limited in diagnosing TBM [127]. 
Comparisons of TBM diagnostic studies are limited by the lack of a clear reference 
standard and low study numbers. Xpert MTB/RIF’s value has not previously been 




processing (centrifuged and uncentrifuged), LOD, effect of CSF-related PCR 
inhibition, and the relationship between CSF bacterial load and Xpert MTB/RIF cycle 
threshold (CT) values have not been determined [56]. 
This study evaluated the accuracy of Xpert MTB/RIF in an unselected cohort of 

























4.2. HYPOTHESIS, AIM AND OBJECTIVES 
4.2.1. Hypothesis 
The Xpert MTB/RIF assay is an accurate point of care TB diagnostic tool using CSF 
as a bio-specimen which will lead to improved diagnosis in patients suspected of 
TBM. 
4.2.2. Aim 
To determine the performance outcomes of Xpert MTB/RIF assay on CSF from TBM 
suspected patients at a tertiary hospital in KwaZulu-Natal, Durban, South Africa vs. 
smear microscopy and liquid culture techniques for the diagnosis of TBM. 
4.2.3. Objectives 
 To determine the diagnostic accuracy of Xpert MTB/RIF assay in smear-
negative and smear-positive patients. 
 To determine Xpert MTB/RIF performance in HIV-infected and -uninfected 
patients. 
















4.3. MATERIALS AND METHODS 
4.3.1. Study Design 
This study was prospectively carried out to determine the performance of the Xpert 
MTB/RIF assay in patients suspected of having TBM who were recruited at local 
district hospitals and referred to the Inkosi Albert Luthuli Central Hospital in 
KwaZulu Natal, Durban, South Africa. Xpert MTB/RIF testing was performed at the 
Lung Infection and Immunity Unit, Cape Town, and Xpert MTB/RIF results were not 
used for patient management.  
4.3.2. Sample size 
In total, 235 consecutive patients with suspected meningitis were prospectively 
recruited. 
4.3.3. Study Flow and Subject recruitment 
Patients with a meningitic illness who were referred from district hospitals were 
recruited. Detailed patient and laboratory specific information was recorded. Written 
informed consent was obtained from the patient or close relatives in cases where 
patients were unable to provide consent, and a lumbar puncture was clinically 
indicated, the Head of Department of Neurology was approached for consent [56, 
128] . Eligible patients who signed the informed consent form had their medical 
history taken and clinically assessed, underwent a computerised tomography (CT) 
scan to exclude contraindications to a lumbar puncture, and had blood drawn for 
routine tests including a serum fluorescent treponemal antibody  test, a venereal 
disease research laboratory test, HIV enzyme-linked immunosorbent assay, and a 
CD4 count [56]. Samples were collected before the patient started TB treatment. All 
results were recorded in the Case Report Form (CRF), which was entered on an 
electronic database. Study participants with incomplete CRF’s were withdrawn and a 
new study subject enrolled instead. Statistical analysis was done using a statistical 
software; OpenEpi (Open Source Epidemiologic Statistics for Public Health, Version 





4.3.4. Classification of patients 
Patient classification was based on standardized published diagnostic criteria, as 
definite TBM if the CSF M. tuberculosis culture and or Amplicor PCR were positive 
or non-TBM (alternate diagnosis confirmed and response to therapy documented in 
the absence of anti-TB treatment) [129, 130]. 
4.3.5. Lab based methods 
Approximately 15 ml of CSF, obtained by lumbar puncture was processed for the 
following tests: microscopy (Gram strain and fluorescent staining for acid-fast bacilli 
[auramine]); bacterial culture; Mycobacterium tuberculosis culture (BACTEC MGIT 
960; BD); fungal culture, cryptococcal latex agglutination test; Roche Amplicor 
Mycobacterium tuberculosis PCR test (Roche Diagnostics System) (Amplicor PCR); 
routine chemistry (protein, glucose and chloride); viral PCR for cytomegalovirus; 
varicella zoster virus, and herpes simplex; venereal disease research laboratory test; 
fluorescent treponemal antibody test; and test for cysticercus antibodies , while an 
uncentrifuged specimen and centrifuged sample of CSF was biobanked for Xpert 
MTB/RIF analysis if there was sufficient volumes available [56]. 
4.3.5.1. Amplicor PCR 
An independent lab processed 197 samples using the Amplicor PCR kit for the 
detection of M. tuberculosis as per manufacturer’s protocol. DNA was extracted from 
0.5 ml of CSF using the Roche Magna Pure automated DNA extraction system using 
the DNA high performance kit where the extracted DNA was then amplified using 
biotinylated primers KY18 and KY75 as described in the Amplicor PCR kit protocol 
[56]. PCR products were detected by the Cobas Amplicor analyser according to the 
kit protocol. 
4.3.5.2. Xpert MTB/RIF  
This test is a fully automated real-time, hemi-nested PCR system [55], developed to 
simultaneously detect M. tuberculosis and rifampicin resistance in a single-use 
cartridge hands free-step [44, 47]. In the initial period of the study, only 1 ml of 
uncentrifuged CSF was obtained for Xpert MTB/RIF testing from 149 patients 
suspected of TBM. Thereafter, so as to assess the impact of centrifugation, a 3 ml 




suspended in 1 ml of phosphate-buffered saline (PBS). In this latter period, if enough 
CSF was available, both a 1 ml uncentrifuged and 3 ml centrifuged sample were 
evaluated i.e. either a 1 ml or 3 ml sample or both was processed for Xpert MTB/RIF 
in patients suspected of TBM [56]. Batched, archived (-70°C) uncentrifuged samples 
(n=149) and centrifuged and uncentrifuged (n=59) were processed at the Lung 
Infection and Immunity Unit (Dept of Medicine, Groote Schuur Hospital, University 
of Cape Town) for Xpert MTB/RIF analysis. Lab technicians performing the CSF 
culture, Xpert MTB/RIF assay and Amplicor were blinded to all participant details. 
Samples for Xpert MTB/RIF test were prepared according to the manufacturer’s 
instructions [98]. Frozen, unprocessed samples were immediately processed with the 
CSF-sample reagent mixture shaken and incubated at room temperature for a total of 
15 minutes with a second shake at 10 minutes. 2 ml of the digested mixture was then 






4.4.1. Study population and TB diagnoses 
 
prospective cohort (n=235) 
152 pts with evaluable results for this analysis
MGIT culture (n=152), Smear microscopy (n=152), Xpert MTB/RIF 







+ve(centrifuged; 8 +ve; 
4 -ve; 25 ND)
3.Smear +ve(1 +ve; 36 -
ve)
4.Culture +ve(30 +ve; 7 
-ve)
4 HIV -ve
1.Xpert MTB/RIF +ve (uncentrifuged; 
0 +ve; 4 -ve; 0 ND)
2.Xpert MTB/RIF +ve (centrifuged; 0 
+ve; 0 -ve; 4 ND)
3.Smear +ve (0 +ve; 4-ve)
4.Culture +ve (3 +ve; 1 -ve)
Probable TBM (n=54)
45 HIV+ve
1.Xpert MTB/RIF +ve 
(uncentrifuged; 2 +ve; 43 -ve; 0 
ND).
2.Xpert MTB/RIF +ve 
(centrifuged; 0 +ve; 0-ve; 45 
ND)
9 HIV -ve
1.Xpert MTB/RIF +ve 
(uncentrifuged; 0 +ve; 9 -
ve; 0 ND)
2.Xpert MTB/RIF +ve 




1.Xpert MTB/RIF +ve 
(uncentrifuged; 3 +ve;  46 -
ve; 0 ND)
2.Xpert MTB/RIF +ve 
(centrifuged; 0 +ve;  0 -ve; 
49 ND).
8 HIV -ve
1.Xpert MTB RIF +ve (uncentrifuged; 0 
+ve; 8 -ve; 0 ND)
2.Xpert MTB/RIF +ve (centrifuged; 0 +ve; 
0 -ve; 8 ND)
 
Figure 19: Summary flow chart showing patients included in the analysis and diagnostic testing performed. 




235 patients with suspected TBM were recruited in this study. However for this 
particular analysis, 152 patients had evaluable results, Figure 19. Of the 152 patients 
included, 131 (86%) were HIV-infected, while 21 (14%) were HIV-uninfected, Figure 
19. 41 of the 152 patients (27%) were definite TBM cases, and 57 (38%) of the 152 
patients were non-TBM, Table 13.  
 









Median age/ yrs 26.5 43 0.86 
Male 18 (44) 20 (35) 0.39 
Female 23 (51) 37 (65) 0.39 
Ethnic group    
Black 40 (98) 56 (98) 0.84 
Mixed 1 (0.03) - NA 
Indian  1 (0.02)  
HIV infected pts 37 (90) 49 (86) 0.55 
HIV uninfected pts 4 (0.1) 8 (14) 0.55 
Median CD4ƚ count 
(cells/µl) if HIV 
+ve 
75.5 69.5 0.07 
Previous TB≠ (%) 8 (20) 21 (36.8) 0.06 
NA, not applicable; TB, tuberculosis; +ve, positive. 
ƚnine patients with HIV infection were missing CD4 count. 






4.4.2. Diagnostic accuracy of Xpert MTB/RIF performed on CSF 
Out of the 35 definite TB (culture-positive or Amplicor-positive) patients in this 
cohort, 17 had Xpert -positive CSF. Xpert had sensitivity of [49% (33 - 64%); 
p≤0.001; Table 14] which as significantly higher than smear microscopy performed 
on the same CSF, having sensitivity of 3% (1 - 15%). 7 of the 117 non TB cases 
(culture-negative or Amplicor-negative) had Xpert -positive CSF with a specificity of 
94% (110/117; 88- 97%) equivalent to that of smear microscopy [100% (11/117; 97 - 
100%); p=0.785, Table 14]. The positive predictive value (PPV) of Xpert was 71% 
(51 - 85%; 17/24) which was similar to that of smear microscopy, 100% (21 - 100%; 
1/1; p=0.720), while the negative predictive value (NPV) of Xpert, 86% (110/128; 79 
- 91%; p=0.072) was similar to that of smear microscopy, 78% (117/151; 70 - 83%). 
 
4.4.3. Impact of CSF centrifugation on Xpert MTB/RIF performance 
CSF centrifugation resulted in an increase in sensitivity of Xpert from 49% (17/35; 33 
- 64%) to 94% (17/18; 74 - 99%), however this increase in sensitivity was not 
significant, p=0.008, Table 14.  
 
4.4.4. Accuracy of Xpert MTB/RIF in HIV coinfected patients 
In HIV-infected patients, centrifugation of CSF resulted in the sensitivity of Xpert to 
be 100% (8/8; 68 - 100%; p=0.014, Table 14) which was significantly different from 
Xpert performance in uncentrifuged CSF (53%; 17/32; 37 -69%). The PPV of Xpert 
on centrifuged CSF was 94% (17/18; 74 - 99%; p=0.065) which was similar to Xpert 
performance on uncentrifuged CSF, 71% (17/24; 51-85%). NPV of Xpert in 
centrifuged vs. uncentrifuged CSF was similar (86% vs. 86%, p=0.919), respectively. 
 
4.4.5. Xpert MTB/RIF performance in smear-negative patients 
In smear-negative patients Xpert MTB/RIF had a sensitivity of 49% (17/35; 33- 64%) 
and a specificity of 94% (110/117; 88 - 97%), Table 14. The PPV of Xpert MTB/RIF 
in smear-negative patients vs. Xpert in unprocessed CSF was the same (71% vs. 




4.4.6. Diagnostic accuracy of Xpert MTB/RIF performed on CSF 
Table 14.Accuracy of Xpert MTB/RIF performed on CSF and stratified by HIV 
status of patients. (Liquid culture positivity for TBM serves a reference standard). 
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MTB/RIF performed on 
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MTB/RIF performed on a 
re-suspended pellet 

































































CSF, Cerebro spinal fluid; NPV, negative predictive value; PPV, positive 
predictive value; TB, tuberculosis. 
+P-values marked with a+ are for comparisons according to HIV-status. 
ƚP-values marked with aƚ are for comparisons between Xpert MTB/RIF and 
smear microscopy. 
≠P-values marked with a≠ are for comparisons between Xpert MTB/RIF and 
Xpert performed in smear-negative patients. 
βP-values marked with aβ are for comparisons between Xpert MTB/RIF 
centrifuged and Xpert MTB/RIF uncentrifuged 
0 – means incalculable, as there were too few HIV-uninfected patients to 
generate reliable accuracy data 
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4.4.7. Xpert MTB/RIF quantitative information and bacterial load analysis 
There was no correlation between Xpert MTB/RIF CT CSF values and time to 
























Figure 20: Relationship between Xpert MTB/RIF-generated cycle threshold (CT) 

















Xpert MTB/RIF evaluation in biological fluids other than sputum is of paramount 
importance as it guides its usage and administration in managing patients suspected of 
having TB. The key findings of this study included: (1) Xpert is likely an important 
rule-in test for the diagnosis of TBM in patients with HIV where it outperformed 
smear microscopy, which is relevant in TBM patient management and treatment 
outcomes; (2) sample processing, such as centrifugation of the CSF improved 
sensitivity particularly to HIV-infected patients in this analysis.  
Limited data exists in relation to Xpert MTB/RIF performance in TBM [131]. 
Available studies evaluating Xpert MTB/RIF on TBM either have too few CSF data, 
such as in a study by Hillemann et al. [52],where nineteen CSF samples were 
evaluated as part of a bigger study of extrapulmonary samples and had a specificity of 
100% with a combined sensitivity of 77%; while also in a survey in Greece by 
Ioannidis et al. [132], the sensitivity of Xpert MTB/RIF was 100% but of note is the 
fact that CSF constituted about 17% of the total constituent of extrapulmonary 
specimens showing the smaller number of samples at hand. Tortoli et al. [55] showed 
that Xpert MTB/RIF test had a sensitivity of 85%, however the study had a lower 
number of culture-positive confirmed cases and the fact that the study was performed 
in a non-TB endemic country suggest otherwise regards its usefulness in a high TB 
endemic area even though the study cohort is predominantly high with 1476 
specimens. Thus all of these studies [52, 55, 131, 132], have small numbers of 
microbiologically proven TBM cases ranging from 0 to 23, where CSF related data 
constitutes a smaller percentage of the total constituent of samples being studied as 
they are mainly laboratory based evaluations of EPTB samples in low TB burden 
countries.  
There was no correlation between Xpert MTB/RIF CT values and TTP in this study, 
which is different from findings in a sputum based study by Theron et al. [133], 
where they found that sputum bacillary load was elevated in tuberculosis patients who 
were less immunosuppressed. 
In this study in HIV-infected patients having centrifuged CSF samples, Xpert 
MTB/RIF had a high sensitivity of 100%; highly suggestive that in areas with high 




study carried out in South Africa [36] , it was reported that centrifugation of urine 
improved the diagnostic yield when Xpert MTB/RIF test was used in HIV-infected, 
sputum scarce patients. This is in accordance with our findings when a similar amount 
of CSF was used resulting in sensitivity of 100%. 
Centrifugation works in CSF possibly due to the fact that the fluid is always readily 
available and is sterile and isn’t made in response to an infection so in cases of 
infection the bacilli is within the fluid such that when one collects the CSF and 
concentrates it, chances are highly likely that the bacilli or test material is sedimented 
and pelleted, the same with urine. However, the same can’t be said for BALF, a 
possible explanation being that the bugs are out-diluted as approximately 300 ml of 
saline is added to the compartment and at least 150 ml of fluid is retained, so in the 
process some bacilli might be lost such that even when centrifugation is done there 
will be too few if any bacilli available for pelleting.  
Xpert MTB/RIF in this study performed with a higher sensitivity compared to other 
commercially available tests. In a study by Causse et al. [50],in Spain, Xpert 
MTB/RIF sensitivity was reported to be 95% against 78% for the Cobas TaqMan 
MTB, where in another survey in Germany, the Cobas Amplicor MTB assay had 
sensitivity of 66% [125]. Jonsson et al. [134], in their study with a cohort of 154 
samples of CSF they analyzed using the Cobas Amplicor MTB assay, sensitivity and 
specificity was found to be 56% and 97%, respectively. All this information is 
suggestive that our findings prove that the Xpert MTB/RIF test performed 
considerably much better than the commercially available tests presented herein. 
However, a likely possible explanation to this improvement in performance was likely  
probably due to the CSF processing (centrifugation) which is likely to concentrate  
and sediment bacilli and rather technical modalities such as efficient extraction and 
fractionation protocols which are automated, thus improving amplification [56], while 
also, the fact that our study was carried out in a higher HIV prevalent setting, makes it  
a possibility we had higher bacterial loads in these patients. 
Some of the limitations of the study are that it was undertaken in a highly TB endemic 
area with high HIV co-infection such that its performance might be over emphasized 
such that it needs to be evaluated in other regions of low TB prevalence so as to 




very few numbers of HIV-uninfected patients (less than 25) such that comparisons in 
this group were not possible and that it would be important to know how the test 
performs in this group. The study also shows that the test is useful in determining that 
a patient has TBM, while it omits on how useful the test is in determining that a 
patient doesn’t have TBM necessitating the need for further research into improving 
sensitivity of the assay.  
 
Conclusion 
The study suggests that the Xpert MTB/RIF has more rule-in potential and is a good 
diagnostic test of TBM in HIV-infected patients in TB-endemic settings, when 



















5. CHAPTER  5 
 
DISCUSSION AND OVERALL CONCLUSIONS 
 
5.1. THE ACCURACY OF LAMP IN TB DETECTION ON SPUTUM 
The use of the LAMP test to diagnose TB suspects within primary health care 
facilities and microscopy centres in high burden settings seem to be feasible, though 
further development is required to improve on the stability and sensitivity of the 
assay. The assay is a promising rule-in test but specificity remains sub-optimal at  
91%. Use of the LAMP test in a targeted approach in cases of HIV co-infection did 
not impact on the sensitivity and specificity of the LAMP test i.e. the assay performed 
the same in these sub-groups of patients (70%; in HIV-infected patients  vs. 85% in 
HIV-uninfected patients; p=0.162). Those patients that were LAMP-positive had a 
significant shorter time to culture-positivity than the LAMP-negative patients. The 
LAMP test does not have incremental value over smear microscopy though it aids in 
improved case detection. The assay had modest sensitivity, 77%, which might be 
improved in future further studies probably through assessing the performance on 
non-sputum samples (CSF, BALF, urine etc), and also maybe through varying 
specimen morphological characteristics such as viscosity, appearance (bloody or not), 
specimen processing (centrifugation), which might possibly lead to improved 
sensitivity of the test leading to increased TB diagnostic potential in high burden 
settings. However, it should be noted that these are preliminary data and the test, 
though feasible, is not yet ready for use given the high false-positive error rate for use 
in the clinical diagnosis of TB. 
 
5.2. THE XPERT MTB/RIF ASSAY ON BALF IN THE DETECTION OF 
TB 
The Xpert MTB/RIF assay is a promising rule-in test having a specificity of 96% 
when performed on BALF from prospective, sputum-scarce, and or smear-negative 
TB suspects within a high burden setting. Centrifugation of the BALF increased the 




However, bronchoscopy is not yet widely available in marginalized settings where the 
burden of HIV, sputum-scarce and or smear-negative TB is highest. Our study has 
more relevance and gives guidance in low incidence settings, where bronchoscopy is 
readily available. Larger multicentre studies are necessary to properly evaluate and 
document whether such diagnostic tests such as Xpert MTB/RIF can be used 
especially given the underperformance of smear microscopy, while also given the lack 
of readily available expertise in marginalized settings, sputum induction can be 
assessed to determine the performance outcomes of Xpert MTB/RIF testing on 
sputum-scarce and or smear-negative TB patients. 
 
5.3. XPERT MTB/RIF ASSAY ACCURACY USING TRACHEAL 
ASPIRATES TO  DIAGNOSE TB 
Mechanically ventilated patients subjected to testing by Xpert MTB/RIF in a single 
randomized control trial had the test having an overall sensitivity of 91% 
outcompeting smear microscopy which thus reduces empirical treatment of patients, 
while also having a potential on drug susceptibility testing and accelerated turn-
around time especially in a high burden setting like where our study was undertaken. 
As a result of the predominantly high NPV (98%) and PPV (83%), Xpert in this 
instance can be a useful rule-out test which is important in deciding isolation release. 
HIV infection did not impact on the diagnostic accuracy of the Xpert MTB/RIF. Of 
the patients with positive Xpert MTB/RIF results, 6/12 were smear-negative, and thus 
Xpert MTB/RIF increased the diagnostic yield by 50%. It would be interesting to look 
at specimen specific factors such as viscosity, salt concentration and appearance 
(bloody or not) especially for tracheal aspirates on their influence on the test as salts, 
proteins and or cellular debris are commonly found in non-sputum samples, while 
also sample processing (centrifugation; can enrich the cellular debris and salts 
mentioned herein) which can interfere with the amplification process and thus inhibit 





5.4.  XPERT MTB/RIF ACCURACY USING CSF TO DIAGNOSE TBM 
Xpert MTB/RIF testing has more rule-in potential for TBM diagnosis in a targeted 
population of HIV-infected patients having specificity of 86%. The suboptimal 
sensitivity of Xpert MTB/RIF on CSF might be as a result of the presence of 
inhibitors, and the paucibacillary samples which were below the detection threshold 
of the assay. However, the rather high sensitivity of 100% when centrifuged samples 
from HIV-infected patients were tested, suggest that the test in higher burden settings 
coupled with HIV co-infection poses as a new standard of care in diagnosing TBM. 
There were too few HIV-uninfected patients (n=4) in this cohort of definite TB 
patients which might lead to misleading results on the performance outcome of the 
test such that we were unable to meaningfully compare this group. Studies should be 
undertaken in different geographical settings of low TB incidence, in HIV-uninfected 
populations and coupled with varying the sample processing methods (CSF volume, 
centrifugation etc) so as to clarify the performance outcomes and the diagnostic 
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